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The ER positive/ HER2 positive molecular subtype accounts for up to 10% of all breast 
cancers, these cancers have a worse prognosis than ER positive/ HER2 negative breast 
cancers. There is considerable evidence that ER positive/ HER2+ positive cancers exhibit 
resistance to endocrine therapy, yet it is unclear what is driving this resistance to therapy. 
The challenge is in identifying, early in the process of treatment decision making, who will 
respond to neoadjuvant letrozole therapy and who might benefit from the addition of 
combined HER2 targeted agents.  
Aims  
1. To investigate which ER positive/ HER2 positive breast cancers respond to 
letrozole. 
2. To compare the mechanisms of resistance to endocrine therapy in ER+/ HER2+ and 
ER+ / HER2- breast cancers. 
3. To determine which cancers should be considered for combined endocrine and anti-
HER2 treatment.  
Methods  
17 postmenopausal women with large, operable, locally advanced ER positive/ HER2 
positive breast cancers treated with neoadjuvant Letrozole had their clinical response 
assessed using periodic 3D ultrasound. Core biopsies were taken at 0, 14 days and 3 months 
of treatment. RNA was extracted, amplified, labelled and hybridised to Illumina HT-12 
whole genome beadarrays. A group of patients with ER positive/ HER2 negative disease 
were identified to compare clinical and molecular response.  
Results 
8 (47%) ER+/ HER2+ patients responded (R) and 9 (53%) patients did not (NR). HER2 
expression was significantly higher at baseline in the NR group (p=0.005). Differences 
between R and NR and between the HER2+/ER+ and HER2-/ER+ groups were evident 
during treatment in terms of rate of change, magnitude of gene expression changes, and in 
change of functional molecular pathways. ER+/ HER2+ responding tumours had similar 
changes in gene expression over 3 months to ER+/ HER2- responding tumours. Analysis of 
responding tumours showed a clear association between good response and up regulation of 
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stromal and immune response genes and down regulation of proliferation genes. In non 
responding tumours, mitogen activated protein kinase (MAPK) signalling and 
phosphoinositide 3-kinase (PI3K) signalling play important roles in resistance to 
neoadjuvant letrozole.  
Conclusions  
• ER+/ HER2+ and ER+/ HER2- responding tumours demonstrate similar gene 
changes in response to neoadjuvant letrozole, suggesting ER rather than HER2 is 
influencing growth in these cancers.  
• ER+/ HER2+ non responding tumours have fewer overall molecular changes on 
letrozole, maintaining high proliferation gene expression and active MAPK and 
PI3K signalling possibly suggesting HER2 signal transduction.  
• This may allow us to select ER+/ HER2+ tumours that will not benefit from 






Breast cancer is the most common cancer in the UK with 55,222 new cases of breast cancer 
being diagnosed in the UK in 2014. Breast cancers with receptors for the hormone estrogen 
are called estrogen-receptor positive or ER positive breast cancer. About 75% of breast 
cancers are ER positive, and these cancers respond well to treatment with hormonal 
therapies, also known as endocrine therapies. In post menopausal women with large or 
locally invading ER positive cancers endocrine therapy can be used to shrink the tumour to 
make it amenable to less invasive surgical resection. Whilst endocrine therapy is very 
effective in the treatment of patients with ER positive breast cancers, many patients will go 
on to develop resistance to endocrine therapy and will have progression or recurrence of 
their disease. HER2 (human epidermal growth factor) is a protein that can affect the growth 
of cancer cells and cancers which are HER2 positive tend to grow more quickly than HER2 
negative breast cancers. ER positive/ HER2 positive cancers account for 10% of all breast 
cancers and there is evidence that these cancers exhibit resistance to endocrine therapy, 
although is unclear what is driving this resistance to therapy. This study investigated the 
response of tumours that were treated with the endocrine therapy letrozole before surgery. 
Biopsies of the tumour were taken before treatment started, and then after 2 weeks and 3 
months of treatment. The clinical response of the tumour was measured by change in size of 
the tumour during the treatment period. With the tissue taken from the tumour biopsies, 
measurements in the expression levels of certain important genes could be recorded and in 
this way we attempted to determine which genes might playing an important role in 
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Breast cancer has been the most common cancer in the UK since 1997, and accounts for 15% 
of all new cancer cases. It is by far the most common type of cancer in women worldwide, in 
the UK breast cancer accounts for 31% of all new diagnoses of cancer in females. In 2015, 
there were 55,170 new cases of invasive breast cancer in the UK: 54,800 (99%) in women 
and 370 (less than 1%) in men, with a female:male ratio of around 148:1,2,3,4 In the same year 
there were 11,400 deaths from invasive breast cancer in the UK. The crude incidence rate 
shows that there are 157 new breast cancer cases for every 100,000 females in the UK, and 1 
for every 100,000 males. It has been estimated that breast cancer affects 1 in 8 women in the 
UK. 
In 2015 there were 7,900 new breast carcinoma in situ cases in the UK. Incidence rates for 
breast carcinoma in situ in the UK are highest in people aged 65-69 years. Over the last 
decade, breast carcinoma in situ incidence rates have increased by 46% in the UK.  
1.1.1 Incidence 
The highest incidence rates of female breast cancer are in older women, supporting a link 
with hormonal status.  In the UK in 2010, 80% of all diagnosis were in the over 50’s, and 
45% were diagnosed in women aged 65 and over (Figure 1.1B).  Age-specific incidence rates 
rise significantly from around the age of 35-39 years, this incidence then levels off for women 
in their 50’s, rises further to the age 65-69 years, drops slightly at 70-74 years, and then 
increases steadily to reach an overall peak over the age of 85 years.  The peaks and troughs 
seen in incidence rates for women aged 50 and over, may partly be explained by the impact of 
screening for breast cancer in this age group. Although very few cases of breast cancer occur 
in women in their teens or early 20s, breast cancer is the most commonly diagnosed cancer in 











Fiure 1.1: Breast Cancer, average number of new cases per year and age-specific incidence rates 
per 100, 000 population, females, UK, 2013-2015.4 
 
 
Since the 1970s, there has been an overall increase of approximately 70% in the incidence of 
female breast cancers in the UK, with an increase of 4% over the last decade (Figure 1.1C).  
This increase is in part attributable to the introduction of the national breast screening 
programme from the late 1980s, and to heightened patient awareness.  However, there has 
been a subtle downward trend in the over 50 population since the mid 2000s, and this is likely 
to be attributable to reduced use of hormone replacement therapy, a known risk factor for 
breast cancer development. 
The incidence of female breast cancer is strongly related to deprivation, with incidence rates 
being lowest for the most deprived women.5 Many breast cancer risk factors are more 
prevalent in more affluent populations, such as late first pregnancy, lower parity, and use of 
hormone replacement therapy. 
 
1.1.2 Risk factors 
Breast cancer can result from multiple environmental and hereditary risk factors.  Incidence 
patterns amongst migrant populations suggest that environmental factors are of greater 
importance.  In developed countries, it has been estimated that genetic factors contribute 
around 25% of the differences in individual susceptibility, whilst environmental and lifestyle 
factors contribute the remaining three quarters.6  However, the strongest risk factor for breast 
cancer, after gender, is age. The older the women, the higher her risk of breast cancer (Table 
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1.1B).  A woman is more than 100 times more likely to develop breast cancer in her 60s than 








1.1.3 Estrogen related risk factors	
A large proportion of breast cancer cases diagnosed in developed countries can be explained 
by factors which influence exposure to estrogen.  These include reproductive factors, obesity, 
alcohol and physical activity.  It has been estimated that around 27% of breast cancers 
diagnosed in the UK are linked to modifiable lifestyle and environmental factors.1 
There are several reproductive factors that increase breast cancer risk. The overall hypothesis 
being the more ovulatory cycles to which the breast tissue is exposed over a lifetime, the 
higher the breast cancer risk.7 Removal of both ovaries has consistently been shown to 
decrease the risk of breast cancer, by about 50% if performed prior to the age of 40 years.8 
Early age at menarche is associated with an increased risk of breast cancer. This is most 
evident at a young age with a twofold increase risk for menarche at 11 years as compared 
with menarche at 13 years.9 Early age at first birth and parity are established, independent, 
protective factors for breast cancer.10,11 Early age at first birth has been shown to provide a 
long-term reduction in breast cancer risk, not evident for approximately 10-15 years.12 
Women with a later age at first birth, approximately 35 years or older, have an increased risk 
of breast cancer, and this risk has been found to be higher than that of nulliparous women.13,14 
Parous women have a reduced risk of breast cancer compared to nulliparous women and the 
protective effect of full term pregnancy increases with number of births.13,14  Women in 















developed countries.  This variation can be explained by the fact that women in more 
developed countries have on average fewer children and a shorter duration of time spent 
breastfeeding. Most studies demonstrate an increased risk for breast cancer in women who 
have a late natural menopause at age 55 years or later, as compared with those with a natural 
menopause at age 45 years.8 Women who have undergone the menopause have a reduced risk 
of breast cancer than premenopausal women of the same age and childbearing history.  It has 
been estimated that for each year of increase in age at menopause, there is an average increase 
in breast cancer of 3.6%.15  
High levels of other endogenous hormones such as prolactin and insulin have also been 
associated with increased risk of breast cancer.  Higher levels of prolactin have been 
associated in particular with estrogen receptor positive tumours, however the role of prolactin 
in breast cancer aetiology is far from clear.16 One meta-analysis showed a 27% increased risk 
of breast cancer in women with type 2 diabetes, although this figure decreases to 16% after 
adjustment for BMI.17 Furthermore, Insulin-like growth factor 1 (IGF1) is positively 
associated with breast cancer risk.18	
Use of exogenous hormone preparations including oral contraceptives and hormone 
replacement therapy (HRT) is associated with higher risk of breast cancer. Recent oral 
contraceptive use (within the prior year) is associated with an increased breast cancer risk 
relative to never or former oral contraceptive use. The association is stronger for estrogen 
receptor positive than estrogen receptor negative disease and there is a particularly elevated 
risk with the use of oral contraceptives containing high dose estrogen.19 There is no 
significant increased risk 10 years after stopping use. It has been estimated that around 1% of 
breast cancer in women in the UK are linked to oral contraceptives.	
The risk of post menopausal breast cancer is increased with current use of hormone 
replacement therapy (HRT), and this risk is larger with combined estrogen plus progestin than 
with estrogen-only formulations. The Women’s Health Initiative (WHI) trial of combined 
estrogen plus progestin was stopped early when overall health risks, including invasive breast 
cancer, exceeded benefits.20  	
1.1.4 Non-estrogen related risk factors	
A number of non-estrogen, environmental and lifestyle factors have been implicated in breast 
cancer risk. Breast density is strongly and independently related to the risk of breast 
cancer.21,22 Breasts with a high epithelial content are described as dense in comparison with 
those with a higher fat content. The effect of breast density is independent of endogenous 
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hormones.23 Density is affected by menopausal status, weight, number of children, and 
genetic inheritance. 
 
Obesity as measured by body mass index (BMI), moderately increases the risk of post-
menopausal breast cancer and is one of the few modifiable risk factors for breast cancer. As 
compared to lean women (BMI between 22.5-24.9), postmenopausal women who are 
overweight (BMI 25-29.9) have a 10-20% increased risk of breast cancer, and obese women 
(BMI>30) a 30% increased risk. Women with a BMI <22.5 have a 15% reduction in risk 
compared to women with a BMI of 22.5-24.9. In contrast, obese pre-menopausal women have 
a 20% reduction in breast cancer risk.2 One study estimated that around 9% of breast cancers 
in women in the UK in 2010 were linked to excess body weight.3 The link between BMI and 
breast cancer is likely to be due to hormones. The main endogenous source of estrogen in 
postmenopausal women is the conversion of hormones in fatty tissue.24 Thus, overweight 
postmenopausal women are exposed to increased levels of endogenous estrogen and have 
higher risks of developing breast cancer. The reduced breast cancer risk seen in obese 
premenopausal women may be due to an-ovulatory menstrual cycles in this group.25 
A meta-analysis of 45 studies reported that higher total fat intake increased breast cancer risk 
by 13%.26 A further study has shown a small but significant risk increase for higher intakes of 
saturated, monounsaturated and polyunsaturated fats.27 It has been reported that women who 
eat high levels of saturated have twice the risk of developing breast cancer.28 High intake of 
dietary fibre and fruit have also been associated with reduced breast cancer risk.29,30 
The association between alcohol consumption and breast cancer has been consistently shown. 
The relative risk associated with every unit of alcohol (10g of alcohol) consumed on a daily 
basis is estimated to be 7-12%.31 This is likely to be due to the increased levels of sex 
hormones in people who consume alcohol. It is estimated that >6% of breast cancers 
diagnosed in women in 2010 were related to alcohol consumption.32 
A 15-20% reduction in breast cancer has been shown in postmenopausal women who are very 
physically active.33 The effect of physical activity on breast cancer risk may be due to effects 
on systemic hormone levels, with lower levels of estrogen and testosterone being reported in 
women with higher levels of physical activity.34 It was estimated that >3% of breast cancers 
diagnosed in women in 2010 were linked to women who undertook less than 150 minutes 
moderate physical activity per week.35  
It has been proposed that night shift work could increase breast cancer incidence.36 A 2007 
World Health Organisation review concluded, mainly from animal evidence, that shift work 
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involving circadian disruption is probably carcinogenic to humans.37 However, this has been 
challenged by a recent systematic review of three prospective UK studies of post menopausal 
women: The Million Women Study (522 246 participant), EPIC-Oxford (22 559) and the UK 
Biobank (251 045). When combining the results of these studies, there was no evidence that 
night shift work was associated with breast cancer.38 
The role of smoking in breast cancer risk remains equivocal. There is evidence that women 
who began smoking under the age of 20 years, or before the birth of their first child, have an 
increased risk of breast cancer.39 It is thought that the risk increase for women who smoke 
compared to women who have never smoked is around 10-20%. However, the evidence 
remains inconsistent and more research is required. 
Women with higher birth weight, length, or born to an older mother are at increased risk of 
breast cancer. In these women there is probably a higher exposure to estrogen in utero.40 
There is a 7-11% increased risk of breast cancer per 5cm increment in height.41 The 
underlying mechanism behind this risk is unclear but it is likely that increased height is a 
marker for other exposures that influence breast cancer. It may also be that hormones 
affecting a woman’s height cause an increase in the volume of breast parenchymal tissue, and 
therefore increased susceptibility to breast cancer.  
 
Exposure to ionising radiation is an established risk factor for breast cancer and is strongly 
related to age at exposure.42 There is a 12-25 fold increase for secondary breast cancer in 
women treated with mantle radiation therapy to the chest for Hodgkin’s lymphoma before the 
age of 30 years.43 Women who received sequential diagnostic x-rays to the chest for 
tuberculosis or pneumonia between the ages of 10 and 29 years have a 3 fold increased risk of 
breast cancer.44 In women treated with radiotherapy for breast cancer, the risk of developing 
radiation-induced contralateral breast cancer is stronger among younger women. Women >45 
years of age when treated with radiotherapy for first breast cancer are not at significant risk of 
contralateral breast cancer.45 It was estimated that 1% breast cancers diagnosed in women in 
2010 were linked to radiation exposure. About 46% of these cases were linked to medical 
radiation and the remainder to background, natural radiation.46 Breast screening 
mammograms are associated with a very small number of breast cancers: of 10,000 women 
who are screened every 3 years between ages 47 and 73 years, between 3 and 6 will develop 
cancer during their lifetime secondary to mammogram radiation.47 
 
Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) confer a 
25% breast cancer risk reduction.48 There is evidence that post-menopausal NSAID users 
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have lower levels of estradiol than non-users.49 Regular use of aspirin in postmenopausal 
women is not recommended owing to the increased risk of gastrointestinal haemorrhage 
associated. The use of anti-hypertensive medications for 5 years or longer has been shown to 
increase breast cancer risk by 20%.50 People treated for the autoimmune condition Graves’ 
Disease have a 12% higher risk of breast cancer.51 Diabetics have a 10-23% increased risk of 
breast cancer compared with non diabetics, the association is strongest in postmenopausal 
women with type II diabetes.52 In diabetics, the risk of breast cancer may vary by treatment 
type, with users of metformin and pioglitazone having lower risk.53 
 
Previous diagnosis of breast disease is a risk factor in itself. Women with benign, proliferative 
breast changes without atypia have a 2 fold increased risk of breast cancer, and those with 
atypical epithelial hyperplasia have 4-5 times increased risk.54 However, women with non-
proliferative, benign pathologies including cysts, complex fibroadenomata, ductal papillomata 
and sclerosing adenosis only carry a significantly higher risk of developing breast cancer if 
they have a strong family history of breast cancer. 
Lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH), combined now as 
lobular intra-epithelial neoplasia (LIN), together with ductal carcinoma in situ (DCIS), are 
non-invasive conditions of the breast, which can in some cases develop into invasive cancer. 
Overall, women with LIN are 4-5 times more likely to develop an invasive breast cancer 
compared to the general population. High grade lesions are more likely to develop into 
invasive disease than low grade lesions.55 
A previous diagnosis of breast cancer raises the risk of developing a second primary breast 
cancer by up to 5 fold.56 The risk of a contralateral breast cancer remains higher 2 years after 
diagnosis of a primary breast cancer, with highest risks in women diagnosed before the age of 
40 years.57  
	
Family history	
In developed countries it is estimated that hereditary factors contribute to 25% of inter-
individual differences in susceptibility to breast cancer, with environmental and lifestyle 
factors contributing to the remaining 75%. Epidemiological studies have shown that first-
degree female relatives of women with breast cancer are at approximately twofold risk of 
developing the disease compared to the general population, and risk is higher if the relative is 
diagnosed under the age of 50 years. Although this could be attributable to shared 
environmental or genetic factors, or both, twin studies indicate that most of the excess 
familial risk is due to inherited predisposition.4  However, more than 85% of women with 
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breast cancer have no family history of the disease.  Furthermore, more than 85% of women 
who have a close relative with breast cancer will never develop the disease.	
	
The breast cancer genes	
	
Three well defined classes of breast cancer susceptibility alleles with different levels of risk 
and prevalence in the population have become apparent: rare high-penetrance alleles, rare 
moderate-penetrance alleles and common low-penetrance alleles.  The contribution of each of 
these genes to phenotypic characteristics associated with them, as well as much of their 
biology and clinical utility is still not fully understood. 	
	
Rare high-penetrance breast cancer susceptibility genes	
	
Disease-causing variants in BRCA1 and BRCA2 confer a high risk of breast cancer, 
approximately 10- to 20-fold relative risk. This translates into a 30–60% risk by the age 60 
years, compared to 3% in the general population.4 The prevalence of BRCA1 and BRCA2 
mutation carriers is estimated to be 0.11% and 0.12% respectively, approximately 1 in 450 
women.  The relative risks are higher for early-onset breast cancers, and there are also 
elevated risks of ovarian and other cancers.58,59 Mutations in BRCA1 and BRCA2 cause breast 
cancer by inactivation of encoded proteins, generally by causing premature truncation or 
nonsense-mediated RNA decay.  These genes have been firmly implicated in DNA break 
repair.11 Mutations are infrequent in most populations.  Approximately 1 in 1,000 individuals 
in the UK are heterozygous mutation carries of each gene, there are many different mutations, 
each of which is rare.60,61  Predisposition to breast cancer is transmitted as an autosomal 
dominant trait in families with mutations.  BRCA1 and BRCA2 are recessive cancer genes, 
with mutations becoming homozygous in the cancers which they cause, usually through loss 
of the wild-type allele.  Mutations in BRCA1 and BRCA2 account for approximately 2% of all 
breast cancers, and up to 20% of the familial or inherited genetic component of disease risk. 
Genetic testing for faulty BRCA genes is available on the NHS for women with a very strong 
family history.	
Germline mutations in TP53 cause Li-Fraumeni syndrome, which includes a high risk of 
breast and other cancers, but these mutations are thought to account for a very low proportion 
of familial breast cancer due to its rarity. Cancer predisposition syndromes due to mutations 
in PTEN (Cowden syndrome), STK11 (Peutz-Jeghers syndrome) and CDH1 are also 
associated with elevated risks of breast cancer, although the cancer risks and prevalence of 
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mutations in these genes are not well defined. It is unlikely that mutations in all six of these 
genes together account for more than 20% of the familial risk of the disease.62,63 
 
Rare moderate-penetrance breast cancer susceptibility genes 
 
There are 4 well documented but rare, moderate-penetrance breast cancer susceptibility 
genes, namely CHEK2, ATM, BRIP1 and PALB2.  CHEK2 is a checkpoint kinase involved in 
DNA repair that directly modulates the activity of both p53 and BRCA1 by phosphorylation.  
ATM encodes a checkpoint kinase that has key functions in DNA repair, and which also 
phophorylates p53 and BRCA1. BRIP1 (also known as BACH1) is a binding partner of 
BRCA1 and is implicated in some BRCA1 activities relating to DNA repair. The PALB2 
gene is called the partner and localiser of BRCA2, it provides instructions to make a protein 
that works with the BRCA2 protein to repair damaged DNA and stop tumour growth.  
 
These 4 genes can result in disease-causing mutations by processes of premature protein 
truncation or nonsense mediated RNA decay through nonsense codons or translational 
frameshifts.  In each of the 4 genes, there are multiple different pathogenic mutations, each of 
which is generally very rare.  Disease causing mutations in each gene are found in less than 
1% of the UK population.  Overall, with respect to their effect on protein function, their 
prevalence in the population and their biological consequences, disease causing mutations in 
CHEK2, ATM, BRIP1 and PALB2 bear many similarities to disease causing mutations in 
BRCA1 and BRCA2. However, mutations in CHEK2, ATM, BRIP1 and PALB2 confer less 
risk of breast cancer (2-3 fold risk) than mutations in BRCA1 and BRCA2 (10-20 fold risk). 
Current estimates suggest that mutations in the 4 genes together account for 2.3% of the 
familial risk of breast cancer, compared to 16% for BRCA1 and BRCA2 together.4,60,61,62 
 
Common low-penetrance breast cancer susceptibility genes 
 
A small number of statistically significant, common low-penetrance breast cancer 
susceptibility genes have been reported in different populations.  These genes confer a very 
small increase in the risk of developing breast cancer.  The 7 most frequently described are 
CASP8 (encoding caspase 8, a member of the cysteine-aspartic acid protease family whose 
activation has a central role in apoptosis); FGFR2 (encoding fibroblast growth factor receptor 
2); TNRC9 (otherwise known as TOX3, a transcription factor); MAP3K1 (encoding mitogen-
activated protein kinase1, involved in growth signalling); LSP1 (encoding lymphocyte-
specific protein 1); 2 of the 7 susceptibility loci are on 8q and 2q, in regions with no known 
protein-coding genes. The population prevalence of these genes is high, ranging from 28%-
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87%, but the relative risk associated with carrying a single copy of each risk allele ranges 




Breast cancer classification divides breast cancer into categories according to 
histopathological type, grade of tumour, stage of tumour and the expression of proteins, 
receptors and genes. The purpose of classification is to select the best, tailored treatment. 
Microarray-based gene expression profiling has had a major effect on our understanding of 
breast cancer. Breast cancer is now perceived as a heterogeneous group of different diseases 
characterised by distinct molecular aberrations, rather than one disease with varying 
histological features and clinical behaviour.  
1.2.1 Histopathological Classification 
Type 
Histopathological classification is based upon characteristics seen at light microscopy of 
biopsy specimens. Carcinomas comprise the vast majority of all breast cancers and arise from 
the epithelial component of the breast. Within the large group of carcinomas, there are many 
different types of breast cancer. The first major division is between in situ and invasive 
carcinoma. In situ carcinoma is "pre-invasive" carcinoma that has not yet invaded the breast 
tissue. These in situ cancer cells grow inside of the pre-existing normal lobules or ducts. In 
situ carcinoma has significant potential to become invasive cancer, and that is why it must be 
adequately treated to prevent the patient from developing invasive cancer. 
Invasive carcinoma of no special type (NST; formerly known as ductal carcinoma) accounts 
for 80% of all invasive breast cancers and the remaining special types of carcinoma account 
for the remaining 20%. Of these, invasive lobular carcinoma accounts for 10-15% of invasive 
breast cancers and the remaining cases of invasive carcinoma are comprised of other special 
types of breast cancer that are characterized by unique pathologic findings. These special 
types include colloid (mucinous), medullary, micropapillary, papillary, and tubular. Sarcomas 
are rare cancers that arise from the stromal components of the breast and these account for 
less than 1% of primary breast cancers. 
The 3 most common histopathological types collectively represent three quarters of breast 
cancers. These are invasive carcinoma NST (55% of breast cancers); ductal carcinoma in situ 
(DCIS; 15%); and invasive lobular carcinoma (5%). 
Breast carcinomas are derived from the epithelial cells that line the terminal duct lobular unit. 
Cancer cells that remain within the basement membrane of the elements of the terminal duct 
lobular unit and the draining duct are classified as in situ, or non-invasive.67 An invasive 
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cancer is one in which there is dissemination of cancer cells outside the basement membrane 
of the ducts and lobules into the surrounding adjacent normal tissue. 
The most commonly used classification of invasive breast cancer divides them into ductal and 
lobular types, this division was based on the belief that cancers arise from the ducts and 
lobules. It is now clear that both invasive ductal and lobular cancers arise from the terminal 
duct lobular unit. Invasive lobular cancers can be difficult to diagnose because their pattern of 
single-file cell infiltration does not form a well defined mass lesion that can be readily 
detected clinically or radiologically.67 Inflammatory breast cancer is a form of invasive ductal 
carcinoma which is distinguished clinically from other carcinomas by the inflamed 
appearance of the breast. Inflammatory cancers are more aggressive and are associated with a 
poor prognosis.68 Some tumours show distinct patterns of growth and cellular morphology 
which allow certain types of breast cancers to be identified. Cancers with specific features are 
called invasive carcinomas of special type, while the remainder are considered to be of no 
special type (NST). This classification has clinical relevance as certain special type tumours 
have a better prognosis than tumours of NST. 
Ductal carcinoma in situ (DCIS) is a heterogeneous disease with increased prominence after 
the introduction of breast screening programmes. Before the advent of screening, DCIS 
represented only 2-5% of symptomatic breast cancers, compared with almost 20% of newly 
diagnosed symptomatic cases in the present era and up to half of screen detected breast 
cancer.69,70 Not all patients with DCIS will progress to invasive disease, with proportionate 
estimates ranging from 25%-50% depending on grade of the lesion.71 Not all invasive cancers 
arise from lesions that are recognised histologically as carcinomas in situ, although a phase 
involving increased epithelial proliferation is likely to precede an invasive cancer. DCIS 
represents a late-stage disease in terms of molecular progression, and many genetic mutations 
occur before invasion.70,72  
 
1.2.2 Molecular Classification 
There is substantial tumour heterogeneity consisting of different molecular subtypes, each 
with distinct biological and clinical characteristics.  Cells express proteins on their surface 
and in their cytoplasm and nuclei that act as receptors for chemical messengers, such as 
hormones. The interactions between cell receptors and their ligands have profound effects in 
cellular behaviour. Breast cancer cells express many different types of receptor, currently 
three receptors are known to influence both prognosis and treatment and are included in 
standard breast cancer classification systems. These receptors are the estrogen receptor (ER), 
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the progesterone receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2/ 
neu). Breast cancer cells which do not express any of these receptors are classified as basal 
like, or triple negative breast cancers (TNBC). Triple negative breast cancers (TNBC), which 
are relatively common among BRCA1 carriers, cannot be treated with targeted therapy due to 
the lack of receptor expression. As such, these tumours carry a particularly poor prognosis. 
Approximately half of TNBC’s will respond to chemotherapy.73 
Breast cancer receptor status is determined by immunohistochemistry (IHC), using labelled 
antibodies to ER, PR and HER2 receptors, and is included in the pathologist’s report. 
Fluorescent in-situ hybridisation (FISH) can be used to determine how many copies of the 
HER2 gene are present and is used to determine HER2 status in cases where IHC is 
equivocal. Results of receptor status are critical as they determine which targeted therapies 
will be beneficial. 
Estrogen Receptor 
Estrogens play a crucial role in the development and growth of both normal and neoplastic 
breast tissue. Approximately 75% of breast cancers express the estrogen receptor (ER). ER 
can be quantified by using the Allred scoring system. This scoring system is based on the 
percentage of cells that stain by IHC for ER (score 0-5) and the intensity of that staining 
(score 0-3), added together for a possible total score of 8. This score stratifies cancers into 
those that are likely or not to respond to endocrine therapy.   
ER positive cancers tend to be ER rich, with an Allred score >6. These cancers depend on 
estrogen for their growth and are therefore susceptible to endocrine therapies that act either by 
reducing the levels of estrogen, or by modifying the activity of this hormone. These cancers 
are consequently associated with a better prognosis than ER negative breast cancers. 
Progesterone Receptor 
Approximately 65% of ER positive breast cancers also express the progesterone receptor 
(PR), and this combination increases the likelihood of a good response to endocrine therapy. 
PR is scored in the same way as ER. Very few PR positive, ER negative cancers exist. 
Human Epidermal Growth Factor Receptor 2 
Human Epidermal Growth Factor Receptor 2 (HER2) has been identified as an important 
target for breast cancer.74 HER2 is amplified or overexpressed in approximately 20% of 
breast cancers, and increased HER2 expression correlates with more aggressive breast 
tumours and a poorer prognosis than tumours with normal HER2 expression.75  
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Fortunately, agents that target the HER2 receptor have dramatically improved survival in 
patients with HER2 positive disease. The monoclonal antibody trastuzumab prevents HER2 
receptor activation, and in combination with conventional chemotherapy improves patient 
prognosis.75   
The majority of ER positive tumours are HER2 negative. ER+/ HER2+ tumours account for 
approximately 10% of all breast cancers. 
	
1.2.3 Molecular Subtypes 
 
Recognition of the importance of the ER and HER2 in breast cancer, and the large scale use 
of immunohistochemistry (IHC), has enabled almost every cancer centre in the world to 
differentiate breast cancer patients into 3 major groups: the hormone receptor positive group 
(which expresses the ER and/ or progesterone receptor (PgR), the HER2 positive group 
(which expresses HER2 by IHC or amplification detected by fluoresce in-situ hybridisation 
[FISH]) and the triple negative group (which is negative for ER, PgR, and HER2).76 Latterly, 
the ER positive group has been subdivided into 2 distinct prognostic groups, luminal A and 
luminal B, based on percentage of Ki67 or the presence of PgR.77  
 
1.2.4 Gene Expression Profiling and Intrinsic Subtypes 
Molecular profiling of breast cancer by gene expression studies has provided an important 
tool to discriminate a number of subtypes. These breast cancer subtypes have been shown to 
be associated with clinical outcome and treatment response. In order to elucidate the 
functional consequences of altered gene expressions related to each breast cancer subtype, 
proteomic technologies have provided further insight by identifying quantitative differences 
at the protein level. In recent years, proteomic technologies have matured to an extent that 
they can provide proteome-wide expressions in different clinical materials. This technology 
can be applied to the identification of proteins or protein profiles to further refine breast 
cancer subtypes or for discovery of novel protein biomarkers pointing towards metastatic 
potential or therapy resistance in a specific subtype. 
 
In an mRNA or gene expression array, the expression levels of thousands of genes are 
simultaneously monitored to study the effects of certain treatments, diseases, and 
developmental stages on gene expression. The expression levels can be simultaneously 
monitored to create a molecular portrait of the investigated tumours. In 2000, Perou et al217 
were the first to show that the phenotypic diversity of breast cancers is associated with a 
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corresponding diversity in gene expression patterns that can be captured using cDNA arrays. 
Using a set of 65 surgical specimens of human breast tumours from 42 different patients, they 
produced complementary DNA microarrays representing 8,102 human genes. The tumours 
could be classified into subtypes distinguished by clear differences in their gene expression 
patterns. The data from Perou and colleagues, and from subsequent authors have led 
clinicians and scientists to reconsider the way to differentiate and treat patients with breast 
cancer, and has set new challenges in the search for novel, more targeted therapies. The St 
Gallen International Expert Consensus on the ‘Primary Therapy of Early Breast Cancer 2013’ 
proposed that identification of intrinsic subtypes is most precise using molecular 
technologies.79 Where such assays are unavailable, surrogate definitions of subtype can be 
obtained by immunohistochemistry (IHC) measurements of ER, PgR, Ki67 and HER2 with in 
situ hybridisation, where appropriate.   
Luminal A Subtype 
Luminal A breast cancer is the most common subtype, representing 50-60% of the all breast 
cancers.80 It is characterised by the expression of genes activated by the ER transcription 
factor that are typically expressed in the luminal epithelium lining the mammary ducts. It also 
presents a low expression of genes related to cell proliferation.78 All cases of lobular 
carcinoma in situ are luminal A tumours, as are most infiltrating lobular carcinomas. The 
luminal A IHC profile is characterised by the expression of ER, PGR, Bcl-2, and cytokeratin 
CK8/18, an absence of HER2 expression, a low rate of proliferation measured by Ki67 and a 
low histological grade. The GATA3 marker is expressed at high levels in the luminal A 
subgroup. Patients with this subtype of cancer have a good prognosis, the relapse rate of 
27.8% being significantly lower than that for other subtypes, and survival from the time of 
relapse is also longer (median 2.2 years).80 They have a distinct pattern of recurrence with a 
higher incidence of bone metastases (18.7%) and less than 10% metastases to the central 
nervous system, liver and lung. The treatment of this subgroup of breast cancer is 
predominantly endocrine therapy.  
Luminal B Subtype  
Tumours with the luminal B molecular profile make up between 10% and 20% of all breast 
cancers. They have a more aggressive phenotype than the luminal A subtype, a higher 
histological grade and proliferative index and a worse prognosis. Although bone is still the 
most common site of recurrence (30%), this subtype has a higher recurrence rate in sites such 
as the liver (13.8%). Survival time after relapse is also lower (1.6 years).81 Luminal A and B 
both express ER, although the ER level of expression is lower in luminal B, and since the 
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prognosis with luminal B subtype is much worse, a great effort has been made to identify 
biomarkers that distinguish between these 2 subtypes. There have been attempts to 
differentiate between luminal A and B using the protein expression of Ki67.82 The luminal B 
subtype also often expresses EGFR and HER2, and has an increased expression of 
proliferation genes such as MKI67 and cyclin B1. The luminal A subtype has been defined as 
ER+/ HER2- and low Ki67, while the luminal B subtype has tumours with ER+/HER2- and 
high Ki67 or ER+/HER2+. Importantly however, the technique used to determine Ki67 (cut-
off point to distinguish luminal A and B set at 13.25%) has not been standardised. The St 
Gallen International Expert Consensus on the ‘Primary Therapy of Early Breast Cancer 2013’ 
noted that the absolute values of each IHC parameter/ cut-point may vary between 
laboratories, and that pending improved standardization local experience might best define 
the locally useful cut-points between ‘high’ and ‘low’ Ki67.79 
Whilst luminal B tumours have a worse prognosis than luminal A tumours despite treatment 
with tamoxifen and AI, they respond better to neoadjuvant chemotherapy achieving a rate of 
pathological pCR in 17% (compared with 7% in luminal A). However, this is lower than for 
HER2 + and basal like tumours, with values of 36% and 43% respectively.83 The main reason 
for attempting distinction between luminal A and luminal B tumours is the differing 
implications for the use of adjuvant cytotoxic therapy between these groups. Optimal 
treatment of this subtype of breast cancer is challenging, clinical trial are testing inhibitory 
molecules of the PI3K/AKT/mTOR pathway at different levels, focussing on the treatment of 
luminal B tumours. 
HER2 Enriched Subtype 
15-20% of all breast cancers correspond to this molecular subtype. These cancers are 
characterized by a high expression of the HER2 gene and other genes associated with the 
HER2 pathway and/or HER2 amplicon located in the 17q12 chromosome. These cancers 
exhibit an over-expression of genes related to cellular proliferation. These tumours are highly 
proliferative, 75% have a high histological grade and more than 40% have p53 mutations. The 
IHC profile of ER- /HER2+ cancers does not correspond perfectly with the intrinsic subtype, 
since only 70% of HER2+ tumours classified by microarray have HER2 protein over-
expressed by IHC. Conversely, not all tumours with HER2 amplification or over-expression 
are included in the cluster of HER2 positive subtype in the analysis of micro- arrays.84 In 
addition, a significant number of tumours considered clinically as ER+/HER2+ are classified 
molecularly as luminal B. 
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Whilst the HER2 subtype is characterised by a poor prognosis, over recent years anti-HER2 
treatment has substantially improved survival in both the metastatic setting and in early stage  
disease. This subtype, along with the basal subtype, have a high chemosensitivity, with higher 
response rates in neoadjuvant chemotherapy studies compared with those seen in luminal A 
and B tumours. 
Basal-like Subtype/ Triple Negative Breast Cancer 
This subtype represents 10-20% of all breast carcinomas. These cancers express genes usually 
present in normal breast myoepithelial cells, including high molecular weight cytokeratins 
CK5 and CK17, P-cadherin, caveolin 1 and 2, nestin, CD44 and EGFR. They are clinically 
characterised by their appearance at an early age, predominantly in women of African origin, 
having a large tumour size at diagnosis, a high histological grade and a high frequency of 
positive lymph nodes.85  
Basal-like tumours tend to be infiltrating carcinomas of no special type with a high mitotic 
index, tumour necrosis, expanding margins and a clear stromal lymphocytic infiltrate.86  They 
have an aggressive pattern of metastatic relapse predominantly of lung, CNS and lymph 
nodes.81 An important feature of this subtype is the absence of ER, PGR and HER2 receptors. 
Therefore, in clinical practice this subtype is often referred to as the Triple Negative Breast 
Cancers (TNBC). A ‘Basal Core Group’ of 5 IHC markers: ER, PGR, HER2, EGFR and 
CK5/6, can be used to classify this subtype with a specificity of 100% and sensitivity of 
76%.87 
Basal-like tumours have a high rate of p53 mutations, which may account for their aggressive 
behaviour and poor prognosis.88 Furthermore, tumours with germ line mutations in the 
BRCA1 are located in the basal-like subgroup in the classification by intrinsic subtypes.89 
Despite having a good response to chemotherapy, they have a worse overall prognosis than 
luminal tumour tumours, with a higher relapse rate in the first 3 years.90 Identifying new 
therapeutic targets to treat this aggressive group of cancers is imperative.   
‘Normal’ Breast Subtype 
These tumours potentially account for 5-10% of all breast carcinomas. They are poorly 
characterised and have been grouped into the classification of intrinsic subtypes with 
fibroadenomas and normal breast samples. They do not express ER, PGR or HER2 and so can 
also be classified as triple negative, although they are not considered basal-like as they are 
negative for CK5 and EGFR. They do not respond well to neo-adjuvant chemotherapy and 
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due to their rarity there are few studies on this subtype. Indeed, there are doubts about their 
real existence and some researchers believe that they could be a technical artefact from high 
contamination with normal tissue during microarrays.91  
Claudin-Low Subtype 
This subtype was identified in 2007, after the initial molecular classification of subtypes. This 
group is characterised by a low expression of genes involved in tight junctions and 
intercellular adhesion, including claudin-3, -4, -7 cingulin, ocludin and E-cadherin, hence the 
name claudin-low. This subtype is located in the hierarchical clustering near the basal-like 
tumours, and both these subtypes share some characteristic gene expression such as low 
expression of HER2 and luminal gene clustering. Unlike the basal-like subtype, the claudin-
low tumours overexpress a set of 40 genes related to immune response, indicating a high 
infiltration of tumour immune system cells.92 They have a low expression of genes related to 
cell proliferation, and they overexpress a subset of genes closely linked to mesenchymal 
differentiation and epithelial-mesenchymal transition. These account for 12-14% of tumours 
and clinically they correspond to high grade infiltrating carcinomas of no special type, that 
can present metaplastic or medullary differentiation.93 About 20% of these tumours are 
positive for hormone receptors. They show poor long-term prognosis232 and have a poor 
response to neoadjuvant chemotherapy. 
In 2011 the 12th St Gallen International Expert Consensus for Early Breast Cancer recognised 
the usefulness of these subtype classifications in the therapeutic decision making process.94 In 
addition, the panel accepted that the different breast cancer subtypes can be defined not only 
by genetic array testing but by approximations to this classification using IHC. This Expert 
Consensus established five clinicopathological definitions, luminal A (ER and/or PGR 
positive, HER2 negative, Ki67<14%); luminal B-HER2 negative (ER and/or PGR positive, 
HER2 negative, Ki67≥14%); luminal B-HER2 positive (ER and/or PGR positive, HER2 
positive, any Ki67); HER2 positive-non luminal (ER and PGR negative, HER2 positive) and 
Triple Negative (ductal) (ER and PGR absent, HER2 negative). It has been accepted that 
luminal A disease generally requires only endocrine therapy which also forms part of the 
therapy of the luminal B subtype. Chemotherapy is considered the recommended treatment 
for most luminal B, HER2 positive and Triple Negative disease.80 The evidence given by the 
multiple studies that evaluate these gene expression based platforms supports that they are 
valuable prognostic tools. The information they provide helps clinicians predict more 





It is known that earlier diagnosis of breast cancer is more likely to result in a favourable 
outcome.  Regardless of tumour type or grade, the smaller a breast cancer is at the time of 
diagnosis, the more likely it is that it has not spread beyond the breast. As a result, the current 
strategy for reducing breast cancer mortality is to seek diagnosis as early as possible.  Early 
detection and improvements in treatment have led to a 30% reduction in breast cancer 
mortality in the UK in all age groups over the past 30 years. 	
1.3.1 Triple assessment	
Most breast cancer patients present with a painless lump. Many, particularly young women 
present to the breast clinic with pain but this symptom is not related to diagnosis of breast 
cancer.    All patients with a lesion suspicious of breast cancer should undergo a triple 
assessment process.	
Triple assessment comprises of 3 equally weighted categories:	
I) Thorough clinical examination of both breasts and the regional lymph nodes in 
the axillae and supraclavicular fossae.	
II) Radiological imaging of the affected breast with or without additional ultrasound 
of the breast depending on the patients age and breast density.	
III) Biopsy of the breast lesion by either fine needle aspiration (FNA) for cytological 
assessment, trucut core biopsy for full histological assessment, or both, 
depending upon local clinic facilities. 	
1.3.2 Radiological imaging and the NHS Breast Screening Programme 
Mammography 
Mammography is performed on symptomatic women over the age of 35 years.  Under the age 
of 35 years the breast tissue is radio-dense, limiting the value of mammography in these 
women.  Two views, oblique and cranio-caudal are obtained to allow detection of mass 
lesions, parenchymal distortion and breast micro-calcifications, which may require further 






The NHS Breast Screening Programme 
All UK women aged between 50 and 70 years, and who are registered with a GP, are invited 
to attend the breast screening programme. The screening is in the form of mammography. In 
2010 2,020,000 women attended, out of 2,750,000 invited for screening, and 16,500 cancers 
were detected.  
Some experts have questioned the overall benefit of screening in terms of reduced breast 
cancer mortality and how substantial the harm is in terms of over-diagnosis, which is defined 
as cancers detected at screening that would not have otherwise become clinically apparent in 
the woman’s lifetime. An independent UK panel conducted a review on breast cancer 
screening in 2012 concluded that screening reduces breast cancer mortality but that some 
over-diagnosis occurs.69 From this review, it was estimated that for every 10000 UK women 
aged 50 years invited to screening for the next 20 years, 43 deaths from breast cancer would 
be prevented and 129 cases of breast cancer, invasive and non-invasive, would be over-
diagnosed; that is 1 breast cancer death prevented for about every 3 over-diagnosed cases 
identified and treated. Crucially, this information should be made available in a transparent 
and objective way to women invited to screening so that they can make informed decisions. 
Ultrasound 
Under the age of 40 years, the breast tissue is more dense and in these women breast 
ultrasonography (US) is the most useful diagnostic imaging modality. In older women US is 
used to better define localised palpable, and mammographically detected lesions and to guide 
excision biopsy for diagnosis. Patients with invasive cancer also have axillary US to detect 
nodal disease, and guided biopsy of suspicious lymph nodes.  
US can also be used to monitor clinical response to therapy by measuring tumour size and 
sequential stages during a patients treatment.   
Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging (MRI) sensitivity is high and can be a valuable tool for 
assessing the extent of invasive and non-invasive disease. Whilst contrast enhanced breast 
MRI has demonstrated a sensitivity of 94%-100% in the detection of breast cancer, its 
specificity has generally been lower and more variable with ranges from 37%-97%. This tool 
is not in routine clinical use for breast cancer diagnosis and assessment. MRI is indicated in 
patients for whom a potential benefit of local staging is expected including women with 
mammographically heterogeneous or extremely dense breasts, at high risk for breast cancer 
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diagnosed with invasive lobular carcinoma and/ or with multifocal, multi-centric or 
contralateral disease. It is used in the screening of high-risk women between the ages of 35 
and 50 years, and is the optimum method for imaging the breast in patients who have had 
previous implant surgery.95 
1.3.3 Breast Biopsy 
Breast biopsy is required of any suspicious palpable lesion. Impalpable or very small lesions 
can be biopsied with the guidance of ultrasound.  
Fine Needle Aspiration Cytology (FNAC) 
This technique can differentiate between solid and cystic lesions. If the breast lesion is 
suspected to be fluid filled and is easily accessible then FNAC is the preferred biopsy 
technique. Tissue is extracted for cytological analysis that can quickly differentiate between a 
benign and a malignant lesion. The advantages of FNAC over core biopsy are: the results are 
readily available, often during the clinic; quicker to perform; local anaesthetic is often not 
required; less traumatic and so more appropriate for some patients on anticoagulative therapy. 
The main limitations of FNAC are the inability to discriminate in situ from invasive 
carcinoma and difficulty in rendering a definitive diagnosis in several categories (eg papillary 
breast lesions, atypical hyperplasias). Furthermore, training in smear preparation and 
cytological experience is required for interpretation. Whilst core biopsy is considered best 
practice for non-operative breast biopsy, FNAC is used for sampling axillary lymph nodes. 
Core Biopsy 
The main advantage of core biopsy over FNAC is that this technique provides an 
architecturally intact specimen for full histological diagnosis and can differentiate between 
invasive and non-invasive cancers. It takes longer than FNAC, requires local anaesthetic, and 
results are not readily available. However, in experienced hands this is a highly sensitive and 
specific technique and for this reason it has largely superseded FNAC in the role of diagnostic 
breast biopsy in the clinic. Ultrasound is the imaging method of chose for sampling non-
palpable soft tissue lesions where it provides real time demonstration of the needle traversing 
the lesion. X-ray stereotaxis is used for image-guided biopsy of most indeterminate and 
suspicious microcalcifications, areas of parenchymal distortion/ stellate lesions and small soft 
tissue masses which cannot be adequately visualised by ultrasound. 
The ER, PR and HER2 status should be requested for all invasive breast cancers 




Histological grade is an independent prognostic factor for invasive breast cancer, used 
internationally to aid treatment decisions. Together with lymph node status, tumour size, 
hormone and HER2 receptor status, it gives important information relating to risk of both 
local and distant recurrence, and influences patient management. Grade has significant impact 
on selection of patients for adjuvant systemic therapy after breast conserving surgery or 
mastectomy, and for post-mastectomy radiotherapy.96,97 
The internationally accepted grading system is that proposed by Elston and Ellis (EE)98,99 
based on a cohort of 1951 patients treated in Nottingham, UK between 1973 and 1989 with 
up to 15 years follow-up. Grading focuses on the appearance of breast cancer cells with 
respect to that of normal breast tissues. Normal breast cells are differentiated, meaning that 
they have specific morphological characteristics that reflect their function as part of the breast 
as a whole. Breast cancers have lost their differentiation and the cells have become 
disorganised. Control of cellular division is lost and the cell nuclei become larger and less 
uniform (nuclear pleomorphism).  
The differentiation of breast tumours is graded by consideration of glandular formation, 
nuclear pleomorphism and frequency of mitoses. Each of these are scored using the 
Nottingham Modification of the Scarff-Bloom-Richardson grading system from 1-3, and their 
values are added to produce three overall grades. This derived histological grade is an 
important predictor of both disease free and overall survival. 
Grade I cancers (score 3-5): low grade, well differentiated tumours. These have the 
most favourable prognosis, can be treated less aggressively and are associated with 
the best survival rate. 
Grade II cancers (score 6-7): intermediate grade, moderately differentiated tumours. 
Grade III (score 8-9): high grade, poorly differentiated tumours which have lost many 
of the normal features seen in normal breast cells. They appear large and immature, 
they divide rapidly and have a greater propensity to spread. These cancers are 






1.3.5 Quantification of ER  
ER status is usually measured by IHC, using monoclonal antibodies. It is generally 
considered that there is a bimodal distribution of ER values in which almost all tumours are 
found to be either strongly ER positive or negative, with only a small proportion showing 
intermediate values. 
The Allred scoring system is the ER scoring system used in the UK. The score is a 
combination of the percentage of cells that stain by IHC for ER (on a scale of 0-5), and the 
intensity of that staining (on a scale of 0-3, for a possible total score of 8). 
Percentage score: 
 0= No staining 
 1= Staining in <1% of cells 
 2= 1 to 10% 
 3=10 to 33% 
 4= 33 to 67% 
 5=67 to 100% 
Intensity score: 
 0= Negative 
 1= Weak 
 2= Intermediate 
3= Strong 
Tumours with a score of 6-8 are considered to show strong ER positivity, and those with a 
score of 2-5 are weakly positive.  
 
1.3.6 HER2 Testing 
Given the importance of HER2 as a prognostic and treatment related factor, almost all 
invasive cancers are now tested for the presence of HER2 over expression.100 Various 
methods are used, and guidelines for testing have been produced.101 The most widely used 
method is an IHC test, which is simple, relatively inexpensive, and easily accommodated 
within existing surgical or pathology laboratories. The test classifies HER2 on a subjective 
scale of 0, 1+, 2+, and 3+. Patients with 0 and 1+ are considered to have low expression and 
to be HER2 negative. Patients with 2+ are considered indeterminate and those with 3+ are 
considered to be HER2 positive. This IHC assay is about 90% accurate.102 Various in situ 
hybridisation techniques, which use one or two tags for the centromere on chromosome 17 
and the HER2 gene, are also available.103,104 If the ratio of HER2 to the centromere on 
chromosome 17 is greater than 2.2 then HER2 is considered to be amplified.102 Some centres 
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use this method for all cancers, but most use it only for samples that are indeterminate (2+) on 
IHC. Newer methods that measure mRNA for HER2 are in development.  
1.3.7 Staging 
Following diagnosis and histological classification of a breast cancer, the presence and extent 
of local and distant disease must be assessed. This process is known as staging and is a key 
factor used to define treatment and to assess the chance of successful treatment outcome. 
The most widely used staging system among clinicians is the TNM system maintained by the 
American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control 
(UICC).56 This system codes the extent of the primary tumour (T), regional lymph nodes (N), 
and distant metastases (M) and provides a ‘stage grouping’ based on T, N and M.  The UICC 
system groups combinations of the TNM factors into stages: 
 Stage 0: Non-invasive or in-situ disease. 
 Stage 1-3: Disease confined to the breast and lymph node basins. 
 Stage 4:  Metastatic disease. 
Patients with small tumours (stage I and II) have a low risk of metastatic disease and require 
no further investigations, unless directed by clinical signs and symptoms. For patients with 
larger tumours, and in whom there is clinical suspicion, CT and PET-CT scans should be 
considered. 
TNM is periodically updated based on advances in understanding of cancer prognosis, to 
remain current and relevant to clinical practice. Historically, cancer staging and treatment 
planning was based solely on the anatomic extent of the cancer. Whilst anatomy continues to 
be a key prognostic factor for cancer, the relevance of the TNM staging of breast cancer in the 
era of biomarkers, genomic analysis, and personalised medicine is becoming increasingly 
limited. The emergence of tumour biology as an essential component to breast cancer care has 
allowed clinicians to understand why patients who are staged similarly using the TNM 
staging system have significantly different outcomes based on tumour biology. The 8th edition 
of the AJCC staging manual (effective Jan 2018; UICC Jan 2017), outlines a new prognostic 
staging system that relies not only on the anatomic extent of disease, but also on prognostic 
biomarkers.105 It now encorporates T, N, M and tumour grade; and HER2, ER and PR status. 
The results of a multigene assay should also be incorporated into the prognostic staging for 
patients with hormone receptor positive, HER2 negative, node negative tumours that are 
<5cm. Specifically, a recurrence score (RS) <11 on Oncotype Dx106 denotes a prognosis 
similar to those with T1a to b N0M0 tumours, and they are assigned a prognostic stage of I1. 
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The Oncotype Dx is a genomic assay of 21 genes assessed by reverse transcription 
polymerase chain reaction (RT-PCR). A score <11 denotes a favourable prognosis with a 5 
year distant recurrence-free survival of 99.3% for patients treated with adjuvant endocrine 
therapy alone. 
1.3.8 Staging the Axilla 
The status of the axillary lymph nodes in non-metastatic, lymph node positive breast cancer 
patients is the single most important determinant of overall survival.107,108 In patients with 
invasive breast cancer, full pathological assessment is only complete following surgical 
sampling of the lymph nodes. For patients with pathologically proven axillary lymph node 
involvement, the number of positive lymph nodes correlates with the incidence of distant 
metastases and overall survival, and more than 3 positive nodes is associated with a 13-24% 
locoregional recurrence rate.67  Both the number of involved nodes and their anatomical level 
have predictive value for survival.109 There is axillary lymph node involvement in up to 40% 
of women with early, invasive breast cancer, and as such accurate staging of the axilla is 
critical. 
Pre-operative identification of nodal malignancy allows for prompt and definitive axillary 
surgery. Clinical and radiological assessment of lymph node status is not reliable. Routine US 
of the axilla followed by FNAC or core biopsy of clinically suspicious nodes can detect up to 
40% of patients with axillary node involvement.  
Complete axillary node dissection remains the standard approach for patients who are 
clinically node positive. This involves removal of all tissue between the anatomical 
landmarks of the axillary vein (superiorly), the thoracodorsal bundle (laterally), and the long 
thoracic nerve (medially); 10 to 40 nodes are removed, and this is referred to as a level 1 and 
2 node dissection.110 Level 1 and 2 lymph node dissection surgery is associated with an 
increased risk of adverse outcomes, including lymphoedema (14%), limited shoulder/ arm 
motion (28%), and neuropathic pain (31%).111 A desire to minimize morbidity led to the 
development of the sentinel lymph node biopsy technique.  
Sentinel Lymph Node Biopsy (SLNB) 
The sentinel lymph node is defined as the first node draining the primary tumour in the 
regional lymphatic basin. Various studies have now shown that histopathological examination 
of the sentinel node is reliable in predicting axillary lymph node status in breast 
cancer.112,113,114 With improvements in breast cancer screening, more patients now present 
without palpable or sonographically evident nodal metastases.115 Sentinel lymph node biopsy, 
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first described in 1994, exploits the orderly pattern of lymphatic drainage. Radioactive 
technetium Tc 99m and/ or blue dye (isosulfan or methylene blue), are injected directly onto 
the breast or into the skin of the breast. The first 1 to 4 nodes that take up Tc 99m and/ or blue 
dye are subsequently removed and evaluated for metastases, because these nodes are 
presumed to be those to which metastatic disease would first spread. False negative rates are 
less than 5% in experienced centres. The five year axillary recurrence rate is reported to be 
between 0.5%-1.5% in patients with a negative SLNB,116,117,118 and continues to be low at 10 
years.119 In a meta-analysis of 48 studies including 14959 patients, axillary recurrence rate 
was reported as 0.3% after a median follow-up time of 34 months.120 
For patients with DCIS undergoing breast conserving surgery, surgical assessment of the 
axilla is not recommended. However, SLNB is recommended for patients with DCIS 
undergoing mastectomy, as it is not possible after a mastectomy in the event that invasive 




1.4 Prognosis in Breast Cancer 
Using prognostic factors, patients may be stratified into low or high risk groups, giving a 
relative prediction of the future behaviour of their disease. Prognostic factors are measured 
objectively at the time of diagnosis and can predict clinical outcome independent of therapy. 
Prognostic factors can be divided into clinical, histological and molecular factors. 
1.4.1 Clinical Factors 
Clinical prognostic factors include tumour size, nodal status and presence of metastatic 
disease. Tumour size is measured by the pathologist following surgical excision and 
correlates with survival, with smaller cancers having better survival rates than larger 
cancers.121 
Histological axillary nodal status is the most powerful prognostic factor in breast cancer. 
Survival directly correlates with the number and level of axillary node involvement.122 The 
new TNM staging system includes a definition of micrometastases as one measuring between 
0.2mm and 2mm in diameter. The clinical significance of the micrometastasis is unclear and 
it is treated as node negative disease.123 
5% of patients have metastatic disease at presentation, and have a poorer prognosis than 
patients with localised disease. Predicted survival depends upon the site of metastases, thus 
patients with supraclavicular fossa disease will have a better overall survival than those with 
disease at other sites. Furthermore, patients with bony metastases alone have better survival 
outcomes than those with visceral disease.97,124  
1.4.2 Histological Factors 
The histological type and grade of the breast cancer provide important prognostic 
information, as well as the expected biological behaviour and pattern of spread of that type of 
cancer. Special types of invasive breast cancers, including tubular, mucinous and cribiform 
cancers are associated with a better prognosis than invasive ductal cancer of no special type.98  
25% of breast cancer cases will have lymphovascular invasion and this is associated with 
increased local disease recurrence and short term systemic relapse.125 Currently, there is no 




Patients who have an extensive in-situ component of disease (>25% of the main tumour with 
non-invasive disease) and who have positive margins at the time of resection also have an 
increased risk of local recurrence after breast conserving surgery. These tumours are not 
associated with increased recurrence risk if the resection margins are clear.67 
1.4.3 Molecular and Biological Factors 
The identification of molecular and biological markers that provide prognostic and predictive 
information to add to standard clinical and pathological factors is an exciting area of current 
research. A molecular risk profile will be clinically useful if higher-risk patients can be 
selected for specific treatments and those at lower risk can avoid adjuvant therapies such as 
chemotherapy or radiotherapy, which impair quality of life and increase health-care costs. 
Interest in novel prognostic markers is based on the fact that a significant number of patients 
with early-stage breast cancer harbour microscopic metastasis at the time of diagnosis. Many 
molecular markers that have been studied have both prognostic and predictive value. 
Prognostic markers are indicators of aggressiveness, invasiveness, extent of spread, and thus 
correlate with survival, independent of systemic therapy. Predictive markers allow clinicians 
to expect therapeutic outcomes and decide future treatment plans. 
Clinical decisions regarding breast cancer management are influenced largely by tumour 
expression of ER, PR and HER2. These biomarkers have prognostic and predictive 
significance in breast cancer and have important implications for tumour growth and 
metastatic patterns.  
Estrogen Receptor 
In general, ER positive breast cancers recur at a low but steady rate over time.126 In a recent 
meta-analysis of 62,923 patients with ER positive, early-stage breast cancer, treated with 5 
years adjuvant endocrine therapy, there was a persistent risk of recurrence and death from 
breast cancer for at least 20 years after the original diagnosis.127 ER positive tumours have a 
constant long term recurrence rate of 2% per year.128,129 This contrasts with other breast 
cancer subtypes where recurrences peak early (often within the first three years of initial 
diagnosis) and then decline in frequency thereafter. Overall, ER positive tumours are less 
likely to recur or cause death from breast cancer than other subtypes.130  Tumours that co-
express ER and PR have the best outcomes, which may be driven by better responses to 
endocrine therapy.129  Furthermore, the median survival from diagnosis of recurrence is higher 
for women with ER positive breast cancer than those with ER negative disease.130 Epidermal 
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growth factor receptor (HER1) correlates inversely with ER status and is associated with poor 
survival.131 
HER2 
In the absence of treatment, HER2 positivity is associated with inferior overall survival 
compared with other breast cancer subtypes, regardless of other known prognostic features 
such as age, nodal status, tumour size, tumour grade, hormone receptor status and adjuvant 
treatment.132 However, trastuzumab, the humanised monoclonal antibody which targets 
HER2, has been shown to prolong disease free survival and overall survival, both in the 
metastatic133 and the adjuvant settings.134 In recent years a series of other anti-HER2 agents 
have been developed. The introduction of lapatinib and more recently pertuzumab and ado-
trastuzumab-emtansine are further improving outcomes in the arena of HER2 positive breast 
cancer. Therefore, the median survival for HER2 positive metastatic breast cancer (MBC) is 
now over 2 years.135 
Triple Negative Breast Cancers (TNBC) 
In general, TNBC is associated with a worse prognosis than other stage-matched tumour 
phenotypes, partly reflecting tumour biology and partly due to the lack of validated targeted 
therapies for these patients. The poorer outcome associated with a TNBC phenotype appears 
to be independent of grade, tumour size, nodal status and therapy.136 The overall survival 
from diagnosis of metastases is short in patients with TNBC (7-12 months).137 In contrast to 
ER positive breast cancer, women who do not experience tumour relapse within the first 5 
years of early stage TNBC are likely to be cured.   
Ki67 
An increased expression of cellular proliferation markers, indicative of uncontrolled growth, 
is associated with poor clinical outcomes in breast cancer.138 Immunohistochemical (IHC) 
staining of Ki67, a nuclear antigen that is only present in proliferating cells, has been shown 
to be a reliable marker to quantify the growth fraction of normal and neoplastic cell 
populations.139,140 The Ki67 labelling index is based on the percentage of cells with positive 
Ki67 staining, and correlates with mitotic index. Ki67 is expressed in cells throughout the cell 
cycle, but not during the resting G0 phase, and is thus most frequently expressed in poorly 
differentiated tumours with high rates of mitotic activity.141 Studies have shown that baseline 
tumour Ki67 is a prognostic factor for breast cancer.142,143,144 However, lack of consistency 
across laboratories has limited Ki67’s value. A working group has been formed to create a 
Ki67 reproducibilty study. This reported substantial variability in Ki67 scoring among some 
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of the word’s most experience laboratories. The group concluded that Ki67 values and cutoffs 
for clinical decision making cannot be transferred between laboratories without standardazing 
scoring methodology.145  
 
Novel biological markers 
 
P53, p14ARF, cyclin D1, cyclin E, TBX2/3, and VEGF are novel molecular markers which 
have been identified through their involvement in the regulation of the p53 and RB tumour 
suppressor pathways, DNA damage response, and angiogenesis/ metastasis, which play 
critical roles in human breast cancer. 
 
1.4.4 Prognostic indices  
There are tools in current clinical use which attempt to combine clinical, histological and 
biological factors in order to estimate prognosis and to plan appropriate treatment for breast 
cancers. Examples of such methods include the Nottingham Prognostic Index (NPI),146,147 St 
Galllen consensus criteria,148 the National Comprehensive Cancer Network (NCCN) 
guidelines149 and Adjuvant Online!150 
The NPI is used to determine prognosis following surgery for breast cancer. It is calculated 
using three pathological criteria: invasive tumour size; number of involved lymph nodes; and 
histological grade. The index is calculated using the following equation: 
NPI=: 0.2 x tumour size (cm) + lymph node stage (score 1 for negative 
lymph nodes; 2 for 1-3 positive nodes; 3 for >4 positive nodes) + 
histological grade (score 1 for grade 1; 2 for grade 2; 3 for grade 3). 
The NPI can be used as a risk stratifier in unselected cohorts of operable, early-stage primary 
breast cancer patients. Prognosis worsens as the NPI numerical value increases and by using 
cut off points patients may be stratified into 10 year survival groups. (Table 1.5A) 
Table 1.2: 10 year breast cancer survival according to Nottingham Prognostic Index151 
Nottingham Prognostic Index (NPI) 
Group Index Value 10 Year Survival (%) 
Excellent 2.0-2.4 96 
Good 2.41-3.4 93 
Moderate 1 3.41-4.4 82 
Moderate 2 4.41-5.4 75 
Poor 5.41-6.4 53 




The NPI does not consider any biological or molecular markers and as such could be 
improved to support more accurate personalised management of breast cancer patients. 
Improved prognostication is an extremely promising area of translational clinical genomics in 
which the patterns of altered gene expression in tumors are used to construct classifiers for 
prognostication (gene-expression signatures). Several ‘high throughput’ methods have been 
introduced into research and routine laboratories. These have provided a new approach to the 
analysis of genomic alterations and RNA or protein expression patterns. Gene expression 
microarrays provide a comprehensive view of gene activity in a biological sample. Unlike 
most traditional molecular biology tools, which generally allow the study of a single gene or a 
small set of genes, microarrays facilitate the discovery of novel and unexpected functional 
roles of genes. The power of these tools has been applied to discovering novel disease 
subtypes, developing new diagnostic tools, and identifying underlying mechanisms of disease 
or drug response. However, this technology produces a vast amount of data and introduces 
new challenges in data interpretation, requiring further exploitation of modern computational 
and statistical tools.152 
Some microarray studies have led to the development of commercially available molecular 
testing kits which can be used in the breast cancer clinic. These tools use gene signatures 
which are predictive of response to treatment. To date, only 2 commercial multigene tests 
have received FDA clearance. 
MammaPrint 
The microarray based MammaPrint is used to assess the prognosis in patients less than 62 
years of age with cancers that are lymph node negative or positive (1-3 nodes) and ER 
positive or negative and are smaller than 5cm.153 MammaPrint includes 70 genes including 55 
established genes and 15 genes with unknown function. Patients can be categorized into low 
or high risk cohorts, which has been shown to be more accurate when predicting 5 year 
metastasis free survival than conventional clinicopathological parameters.154 Results are now 
available for the prospective MINDACT trial for MammaPrint. Microarray In Node-negative 
and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial 
demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumours 
are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can 
thus be candidates to avoid this toxic therapy.155,156 
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PAM50 (Prosigna, Nanostring Techologies, USA) 
This is the 2nd FDA approved assay which uses a panel of 50 genes plus 5 housekeeping 
genes to compute a risk of recurrence score which enables to identify the intrinsic BC 
subtypes. PAM50 also provides estimation for distant relapse-free survival and likelihood of 
recurrence at 10 years for ER-positive, tamoxifen treated patients. It was validated in 2 
retrospective trials including more than 2,400 patients and can also support identification of 
node-positive and ER positive patients who do not necessarily need adjuvant 
chemotherapy.157,158   	
Oncotype DX (Genomic Health, USA)   
This test measures the expression of 21 genes including 16 cancer related genes and 5 
reference genes to compute a continuous recurrence score (RS) ranging between 0 and 100.159 
The most important genes in the assay include HER2, ER and Ki67, with highest score given 
to the 2 genes related to the HER2 pathway (HER2 and GRB7). RS is prognostic for ER 
breast cancer treated with tamoxifen regardless of nodal status (up to 3 positive lymph nodes). 
Patients with a low recurrence score (0-10) have a very low risk of recurrence with endocrine 
therapy (ET) alone. Patients with a high RS (26-100) demonstrated poorer outcomes with 
higher event rates despite the addition of chemotherapy to ET. For patients in the mid-range 
RS (11-25), the benefit of adding chemotherapy is uncertain. TAILORx is a trial which 
attempted to bring clarity to the interpretation of this midrange RS group. TAILORx enrolled 
10,273 women, making this the largest breast cancer treatment trial ever conducted. The 
investigators concluded that adjuvant chemotherapy may be spared in all women older than 
50 years with an RS of 11-25 and in 36% of those 50 years or younger. Of patients 50 years 
or younger (14% of the overall population), 64% had an RS of 16-25 and this subset can 
derive some befefit from chemotherapy.160 
1.4.5 Predictive indices 
While prognostic markers correlate with survival independent of systemic therapy, predictive 
markers provide information on the likelihood of a favourable response to a particular 
treatment.  A most important question is regarding adjuvant chemotherapy, since uniform 
treatment for all tumours would result in substantial over or under treatment for the individual 
patient.  
Some prognostic factors are predictive and vice versa. For example in addition to providing 
prognostic information, ER status predicts response to hormone treatment. Similarly HER2 
positivity predicts response to immunological treatment with Trastuzumab (Herceptin), 
	
	 33	
Lapatanib, Pertuzumab and T-DM1 and HER1 (EGFR) positivity to treatment with 
Lapatanib, Pertuzumab and Gefitinib. With this in mind, a number of attempts have been 
made to incorporate prognostic and predictive information into clinically useful tools, which 
aim to provide prognostic and predictive information.  
 
Adjuvant! Online  
 
Adjuvant! online (www.adjuvantonline.com) is a frequently updated site that assists 
healthcare professionals and patients with early stage breast cancer to discuss the risks and 
benefits of adjuvant therapy after surgery. It does this by presenting estimates of the risk of 
cancer-related mortality or relapse, which can be used in patient consultations. Patient details 
including age, health and comorbidities, and details of the tumour including size, nodal status, 
estrogen receptor and HER2 status. The information is processed to provide details of 
recurrence rates and survival with and without adjuvant therapies.  
 
There has been some uncertainty about how applicable the Adjuvant! Model is to patients 
diagnosed and treated in the UK. One study of 1,065 women with early breast cancer treated 
in the UK showed that Adjuvant! overestimated the overall survival by 6%.161 In the UK, 
PREDICT.nhs (www.predict.nhs.uk) is now widely used. This is a mathematical model 
accessed by the internet and designed for patients and doctors to help them decide on the ideal 
course of treatment following breast cancer surgery. The model was developed on 
information collated for 5,694 women who had surgery for invasive breast cancer in East 
Anglia from 1999-2003. Breast cancer mortality models for ER positive and ER negative 
tumours were derived and a prognostication model for early breast cancer that predicts breast 
cancer survival following surgery was developed. Data entry for an individual patient 
includes patient age, tumour size, grade, number of positive nodes, ER status, HER2 status, 
Ki67 status and mode of detection. Survival estimates, with and without adjvant therapy, are 
presented. Treatment benefits for endocrine therapy and chemotherapy are calculated and 
predicted mortality reductions are available for both second generation (anthracycline-
containing) and third generation (taxane containing) chemotherapy regimens.162  It is the first 





1.5 Management Pathways- Local Treatments 
 
The aim of breast cancer treatment is to achieve long-term disease control with minimal 
morbidity to the patient. Most patients benefit from a combination of local and systemic 
therapies. Local therapy includes surgery and radiotherapy and is intended to treat the tumour 
at its site within the breast, and in the axilla, without affecting the rest of the body.  
 
1.5.1 Surgical Management of the Breast  
 
Surgery is considered the primary treatment for breast cancer.  The main aim of surgery is the 
complete resection of the primary tumour with negative margins to reduce the risk of local 
recurrences. Surgery also allows for pathological staging of the tumour and axillary lymph 
nodes to provide necessary prognostic information. Procedures include breast conserving 
surgery (BCS), when tumour is excised with a margin of surrounding tissue whilst preserving 
the healthy breast tissue, and mastectomy.  
 
Large, randomized, clinical trials have reported no significant difference in disease-free and 
overall survival between BCS and traditional mastectomy.165,166,167 BCS is considered to be 
associated with a diminished psychological burden compared with mastectomy, offers better 
cosmetic results, and reduces wound infection risk.168 The most important disadvantage of 
BCS is the lifelong risk for local recurrence, in which case additional surgery is necessary. 
Large clinical trials have reported local recurrence rates between 6% and 16%.169,170 
 
Breast Conserving Surgery 
Breast conserving surgery is the complete surgical resection of a primary tumour with a 1cm 
margin of macroscopically normal tissue, a wide local excision (WLE). It may be performed 
with palpation guidance or by pre-operative localisation with image guidance and placement 
of a wire. It is applicable in most patients with stage I or II invasive carcinomas.  This 
procedure is combined with excision of the sentinel node or all of the axillary nodes. Patients 
who have BCS will subsequently have radiotherapy. 
 
Relative contraindications to BCS include small breast size, large tumour size (>5cm), and 




(i) Multifocal disease 
(ii) History of previous radiation therapy to the area 
(iii) Inability to have radiation therapy for invasive disease 
(iv) First or second trimester of pregnancy 
(v) Persistent positive margins after attempts at conservation. 
 
Accurate localization is essential for adequate surgical removal of breast tumors, in which an 
optimal balance between good cosmetic results and preservation of resection margins is the 
primary goal. Obtaining tumor-free surgical margins decreases the incidence of LR of the 
primary tumor. To ensure the complete excision of all invasive and in-situ disease, specimens 
can be sent for imaging intra-operatively. In the literature, the best reports result in at least 
20% of patients returning to theatre for re-excision of positive margins.171 A negative margin 
of 1-2mm is considered to be accurate.172 Whilst the influence of a ‘close’ margin, usually 
defined as tumour cells being present within >0 and ≤2mm from the cut edge, has been 
controversial, margin ‘closeness’ is currently not seen as an indication for re-excision.173 
Wider margins do not reduce local recurrence further but may adversely effect cosmesis.   
 
Patients with tumours which are too large for routine BCS may be offered neoadjuvant 
medical therapy in order to shrink the tumour preoperatively, rendering if suitable for BCS.  
Neoadjuvant endocrine therapy has been shown to reduce tumour volume to a better extent 
than neoadjuvant chemotherapy, resulting in better rates of subsequent complete excision 
following neoadjuvant endocrine therapy.174,175,176,177 This will be discussed in further detail 
later. Where tumours are too large for BCS, consideration may also be given to oncoplastic 
surgery. Options for breast reconstruction include fasciocutaneous local tissue advancement 
flaps; breast parenchymal local flaps; and latissimus dorsi myocutaneous flaps. These 





Patients not suitable for BCS will be offered mastectomy. Some patients opt to have 
mastectomy through personal preference, or where the cosmetic result from BCS is deemed 
unacceptable.  
 
A total mastectomy involves complete removal of all breast tissue to the clavicle superiorly, 
the sternum medially, the infra-mammary crease inferiorly, and the anterior axillary line 
	
	 36	
laterally, with en bloc resection of the pectoralis major fascia. The following variants are 
performed: 
• Modified radical mastectomy – A total mastectomy with axillary lymph node 
dissection (ALND) 
• Skin-sparing total mastectomy (SSM) 
• Nipple-sparing total mastectomy (NSM) 
 
Increasingly, skin and nipple sparing mastectomies are performed in conjunction with 
immediate breast reconstruction to achieve optimal aesthetic results. Radical and extended 
radical mastectomy (total mastectomy plus en bloc resection of the pectoralis major and 
ALND, with resection of the internal mammary lymph nodes in the extended procedure) are 
now deemed historical. 
 
1.5.2 Surgical Management of the Axilla 
In patients with invasive breast cancer, the histopathology result from SLNB determines the 
subsequent management of the axilla. Where the sentinel node has no pathological evidence 
of disease, no further treatment to the axilla is required. In patients with a positive lymph 
node, axillary node clearance has long been the treatment of choice to achieve regional 
disease control. The presence and number of cancer-containing lymph nodes detected has 
been used to inform decisions regarding adjuvant chemotherapy and radiotherapy.178 Around 
15-20% of patients will have tumour-positive sentinel lymph nodes after preoperative axillary 
ultrasound, despite no clinically suspicious findings on initial axillary examination.179 There 
are three options in the case of a positive SLNB: proceed to axillary lymph node dissection 
(ALND); irradiate the axilla; observe. Although ALND provides excellent regional control, it 
is associated with harmful side effects. The AMAROS trial was a randomised, multicentre, 
non-inferiority trial in which patients with a positive sentinel node were assigned to receive 
axillary radiotherapy or axillary lymph node dissection. This trial concluded that for the 
treatment of macrometastases (>2mm), axillary radiotherapy and axillary node clearance are 
equivalent in their prevention of regional relapse; but there is less morbidity and/ or 
lymphoedema associated with radiotherapy.180  
In patients with clinically node-negative disease, the sentinel node is the only involved node 
in 40% to 60% of patients undergoing SLNB.112 Completion axillary lymph node dissection 
(ALND) for women with micrometastases or isolated tumour cells (ITCs) is controversial 
because of the uncertain clinical significance of micrometastases and the low yield of 
additional positive axillary lymph nodes.  The American College of Surgeons Oncology 
Group (ACOSOG) Z0011 trial was designed to compare outcomes of patients with sentinel 
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node metastases who were randomised to have completion ALND or managed without 
completion ALND and without third field axillary radiation.181 At a median follow-up time of 
6.3 years, there were no statistically significant differences in local recurrence or regional 
recurrence between the 2 groups.  
The Positive Sentinel Node: adjuvant therapy alone versus adjuvant therapy plus Clearance or 
axillary radiotherapy (POSNOC) trial has recently completed recruitment of 1900 
participants. This is a UK wide randomised, non-inferiority trial for women with early stage 
breast cancer and 1 or 2 sentinel node macrometastases, to assess whether adjuvant therapy 
alone (chemotherapy and/ or endocrine therapy) is no worse than adjuvant therapy plus 
axillary treatment, in terms of axillary recurrence within 5 years. Results of the trial are 
expected to be published after March 2023. 
 
1.5.3 Radiotherapy 
Radiation therapy is an integral part of management in breast carcinoma treatment. Ionising 
radiation can kill malignant cells, as well as normal cells. It works by damaging the cells 
DNA and cancerous cells are more sensitive to radiotherapy than normal cells as they have a 
higher mitotic rate. Careful pre-therapy planning is necessary to optimise targeting the tumour 
tissue within the radiation field and to minimise damage of the surrounding healthy tissues. 
Most radiotherapy is delivered as an external beam, however, brachytherapy in which a 
radiation source is placed within the breast tissue or tumour bed, can be used to further 
minimise exposure to healthy tissue. 
Other considerations must also be made in the context of radiotherapy. Radiotherapy poses a 
cardiac risk and cardiac exposure should always be minimised as much as possible. The risks 
of treatment are however outweighed by the reduction in breast cancer recurrence. 
Furthermore, there is a slight increased risk of lymphoedema and shoulder restriction after 
radiotherapy. 
Current guidelines state that at least 95% of patients should receive radiotherapy within 4 
weeks of BCS or final dose of chemotherapy.182,183 
 
Radiotherapy after breast conserving surgery 
For most patients treated with breast conserving surgery, whole breast radiation therapy is 
recommended. The exceptions to this approach are patients ≥65 years old with node-negative, 
hormone receptor positive primary tumours up to 3cm for whom endocrine therapy is 
planned, where radiotherapy may reasonably be excluded; and for patients ≥50 years old with 
≤3cm, hormone receptor positive, node negative tumours where accelerated partial breast 
irradiation may ba a reasonable alternative to whole breast radiotherapy. 
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Two meta-analyses of individual patient data have shown significant reduction in breast 
cancer recurrence with radiotherapy given after breast conservation surgery.184,185  The rate of 
recurrence is approximately halved at 10 years from 35% to 19.3%. Adjuvant radiotherapy 
should also be offered to patients with DCIS following adequate breast conserving surgery. 
Shorter fractionation schedules can now be used safely in patients with early breast cancer (eg 
4,005cGy in fractions over 3 weeks rather than 5,000 cGy in 25 fractions over five weeks).186 
A randomised control trial comparing intraoperative radiotherapy (IORT) with external beam 
radiotherapy (EBRT) has shown no significant increase in local recurrence after 4 years. 187 
The risk of local recurrence after standard radiotherapy can be reduced by the addition of a 
boost to the tumour bed. Radiotherapy boost is recommended in all patients aged 50 years or 
under at diagnosis and it should be considered in patients over 50 years at diagnosis, 
especially those with high-grade cancers.188 
 
Post mastectomy radiotherapy 
Post mastectomy radiotherapy (PMRT) should be considered in patients with lymph node 
positive breast cancer if they have a high risk of recurrence (≥4 positive lymph nodes or T3/4 
tumours). PMRT results in a three fold reduction in local recurrence at 15 years, with the 
most significant difference in the first five years.189 The results of the SUPREMO trial which 
was set up to determine the benefits of PMRT in women considered ‘intermediate’ risk of 
recurrence are awaited. 
 
Radiotherapy following axillary surgery 
Following complete axillary dissection (level I/II), post operative radiotherapy is deemed 
unnecessary and may add to morbidity. In patients with ≥4 positive lymph nodes, irradiating 





1.6 Management Pathways- Systemic Treatment 
Systemic therapies include chemotherapy, endocrine and biological therapies and may be 




In general patients with an estimated relapse risk of more than 10% over the course of 10 
years are viewed as potential candidates for neoadjuvant or adjuvant chemotherapy. In early 
breast cancer, preoperative chemotherapy is equally as effective as postoperative 
chemotherapy regarding disease-free survival and overall survival.190 Traditional 
chemotherapeutic agents specifically target cells undergoing mitosis, thereby preferentially 
affecting the rapidly dividing cancer cells. In trials of neoadjuvant chemotherapy, 
pathological response has consistently been shown to be a powerful determinant of long-term 
outcome. Patients with a complete pathological resonse (pCR) have a significantly better 
diease free and overall survival.192 
 
The current standard chemotherapies in early breast cancer are anthracyclines and taxanes, 
given as a combination or in sequence over a period of 18-24 weeks. The EBCTCG meta-
analysis suggested that anthracycline containing and taxane containing chemotherapy reduced 
10 year breast cancer mortality by about a third.192 An anthracycline and taxane sequence is as 
effective as their combination.193 Results of several trials in node-positive high risk disease 
have shown that dose-dense chemotherapy improves outcome in early breast cancer 
compared with standard interval chemotherapy.194 Data from chemotherapy trials exist for 
patients with early breast cancer up to about 70 years of age, however biological age is more 
important than chronological age when indicating chemotherapy in elderly patients.193 Dose 
and schedule can be tailored according to the special requirements of an elderly patient, as 
stated by the International Society of Geriatric Oncology (SIOG).195 
 
For patients with triple negative breast cancer, standard regimens containing anthracycline 
and taxane should be used, preferably as neoadjuvant therapy. A 6-9 times higher risk for 
relapse has been reported for patients with TNBC or with HER2 positive breast cancer who 
do not achieve a pCR  with neoadjuvant treatment. Since 2014, trials have indicated that 
adding platinum to a neoadjuvant anthracycline-taxane combination or sequence improves the 
rate of pathological complete response.196,197,198 The results of the GeparSixto trial showed 
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that adding neoadjuvant carboplatin to a regimen consisting of taxane-anthracycline 
chemotherapy and targeted therapy (bevacizumab) substantially increased pCR in patients 
with stage II-III TNBC,199 
 
Metastatic Disease 
In contrast with early breast cancer, metastatic breast cancer is considered incurable with 
currently available therapies, however, the concept of metastatic breast cancer as a chronic 
disease controlled by sequential therapies over a long period is realistic for certain subgroups. 
Next to prolongation of life, therapeutic goals in metastatic breast cancer are maintenance of 
quality of life and palliation of symptoms. Chemotherapy is always indicated in triple-
negative breast cancer, after endocrine options have been exhausted in luminal disease or if 
rapid response is needed in life-threatening situations or in patients who are highly 
symptomatic.194 If not already given in the adjuvant setting, patients with metastatic breast 
cancer should receive anthracyclines and taxanes. Unless patient symptoms require 
combination chemotherapy, sequential mono-chemotherapies are recommended, as 
combination chemotherapy does not prolong survival.200 
 
1.6.2 Biological Therapies 
HER2 positivity accounts for about 20% of breast cancers and is defined as evidence of 
HER2 protein over-expression measured by immunohistochemistry status (IHC3+) or by 
fluorescence in-situ hybridisation (FISH) measurement of a HER2 gene copy number of six 
or more or a HER2/CEP17 ratio of 2·0 or greater. Anti-HER2 treatment for HER2-positive 
breast cancer has changed the natural history of this disease. Trastuzumab (Herceptin; 
Genentech, Inc, USA) is a humanised mouse monoclonal antibody that binds to the 
extracellular domain IV of HER2, thereby inhibiting ligand-independent HER2 and HER3 
signalling. The approval of trastuzumab in 1998 has been a milestone in the treatment of 
HER2 positive breast cancer. It has consistently been shown to improve disease free survival 
(DFS) and overall survival (OS) in early and breast cancer and improved time to disease 
progression and OS in patients with metastatic breast cancer (MBC).201,202,203  However, 
despite appropriate treatment with trastuzumab, up to 40% of patients with HER2 
overexpression may be resistant to therapy (de novo and acquired resistance).204 To combat 
resistance, dual therapy combinations have been trialled, including combination of anti-HER2 
agents with chemotherapy, combination of 2 anti-HER2 agents with complementary 
mechanisms of action targeting HER2/ HER3 dimerization, and testing of irreversible dual 
HER1/ HER2 inhibitors, such as afatinib and neratinib.204 Trastuzumab, combined with 
chemotherapy in the neoadjuvant setting almost doubles the rate of complete pathological 
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response and in the adjuvant setting reduces recurrence and improves survival.279, 280 Newer 
anti-HER2 treatments include lapatinib, a small molecule that blocks HER1 and HER2 
activation, and pertuzumab, a monoclonal antibody that targets HER2 and prevents HER2/ 
HER3 dimerization. Combining either pertuzumab or lapatinib with trastuzumab and 
chemotherapy before surgery appears even more effective than dual treatment with 
chemotherapy and trastuzumab.207,208,209  
Several randomised trials have shown that adjuvant treatment with trastuzumab leads to a 
significant improvement in disease-free survival in women with HER2-positive, operable 
breast cancer. Furthermore, follow up data from the NSABP B-31 and NCCTG 9831 trials210 
and the BCIRG 006211 trial show overall survival rates of 83-86% at 8-10 years in women 
with HER2 positive, operable breast cancer. This is a vast improvement for a disease subtype 
previously associated with poor prognosis. Further studies have investigated ways of targeting 
the HER2 receptor with new drugs and combinations. The ALLTO study212 compared 
trastuzumab with three experimental regimens: lapatinib, lapatinib with trastuzumab, or 
sequential therapy with trastuzumab followed by lapatinib. The net result was that addition of 
lapatinib to trastuzumab did not improve the therapeutic benefit of adjuvant trastuzumab and 
was associated with additional toxic effects that were directly due to lapatinib.  
In a phase III, randomized study, the combination of trastuzumab and lapatinib improved 
progression-free survival (PFS) when compared to lapatinib alone in patients with 
progression of MBC on prior trastuzumab-containing therapy.213 Clinical Evaluation of 
Pertuzumab and Trastuzumab (CLEOPATRA) trial demonstrated a significant improvement 
in OS to 56.5 months in the pertuzumab, trastuzumab, and docetaxel group versus 40.8 
months in the trastuzumab and docetaxel group. Additionally, the PFS and duration of 
response were prolonged in the pertuzumab group, supporting the use of dual HER2 blockade 
in MBC.214 
The latest new agent targeted at HER2 over expressing cancers is ado-trastuzumab (T-DM1; 
Kadcyla®), which is a three part immunoconjugate consisting of trastuzumab, a stable linker, 
and the potent cytotoxic emtansine derivative, DM1. Compared with lapatinib and 
chemotherapy, T-DM1 significantly increased progression-free survival and was better 
tolerated in patients who had progressed while receiving trastuzumab and taxane 
chemotherapy.216 Unlike pertuzumab which has low single-agent activity and must be 
partnered with trastuzumab as part of a regimen that frequently includes anthracyclines and 
taxanes in earlier stage disease, T-DM1 has very good single-agent first line metastatic breast 
cancer activity. The MARIANNE study was designed to assess the efficacy and safety of T-
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DM1 and T-DM1 plus pertuzumab compared with trastuzumab plus taxane in patients with 
HER2 positive, advanced breast cancer and no prior therapy for advanced disease.217 In the 
study, although not demonstrating superiority in PFS to a taxane plus trastuzumab, T-DM1 
was noninferior. Furthermore, the duration of response to T-DM1 with or without pertuzumab 
was 20.7 months and 21.2 months, respectively, versus 12.5 months for a taxane and 
trastuzumab. The single-agent toxicity profile of T-DM1 is also highly favourable given that 
it seldom causes alopecia and is well tolerated subjectively. On the basis of these findings, T-
DM1 may provide an alternate first line treatment option to trastuzumab plus taxane in 
patients with HER2 positive metastatic breast cancer.  
In April 2017 the Scottish Medicines Consortium approved the use of T-DM1 for the 
treatment of patients with HER2 positive, unresectable lovally advanced or metastatic breast 
cancer who previously received trastuzumab and a taxane. Of note is that Pertuzumab, 
following a second submission for approval in June 2017, is not approved by the Scottish 
Medicines Consortium and as such is not available for prescription on the NHS in this 
country. 
1.6.3 Neoadjuvant Trials of anti-HER2 therapies 
In the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) 
trial, a phase III, multicenter study, pCR was significantly higher in patients treated with 
lapatinib and trastuzumab than with trastuzumab alone (51.3% vs 29.5%, p=0.001).218  
Furthermore, in women who achieved pCR in the NeoALTTO study, there was a statistically 
significant improvement in both event free survival (EFS) and overall survival (OS).219 The 
CHER-LOB trial (Chemotherapy, Herceptin and Lapatinib in Operable Breast Cancer) also 
demonstrated significant improvement in in pCR with dual therapy compared to trastuzumab 
or lapatinib alone, demonstrating an 80% increase in pCR rate.  
Trastuzumab in combination with pertuzumab in the neoadjuvant setting has also been 
investigated. In the NeoSphere trial patients were assigned to 1 of 4 treatment arms: 1) 
trastuzumab alone with docetaxel; 2) pertuzumab alone with docetaxel; 3) trastuzumab and 
pertuzumab with docetaxel; or 4) trastuzumab and pertuzumab without chemotherapy prior to 
breast surgery.220 Results demonstrated that patients who were given pertuzumab and 
trastuzumab plus adjuvant docetaxel had a significantly improved pCR (45.8%) compared 
with those given trastuzumab with docetaxel (29%) or pertuzumab with docetaxel (24%; 
P=0.01). These results were considered practice changing and drove the FDA approval of 
pertuzumab for neoadjuvant treatment of HER2+ BC. Notably, the dual anti-HER2 therapy 
without chemotherapy arm resulted in a pCR rate of 16.8%, which could suggest a potential 
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role for a treatment regimen without chemotherapy in select groups of patients who may not 
be candidates for cytotoxic chemotherapy.  
Most recent results from the ADAPT trial of ER positive/ HER2 positive breast cancers, are 
particularly relevant to the current study of ER positive/ HER2 positive breast cancer.221 In 
this prospective, neoadjuvant, phase II trial, 375 patients with early breast cancer with HER2 
positive and HR positive status were randomly assigned to 12 weeks of T-DM1 with or 
without endocrine therapy or to trastuzumab with endocrine therapy. The primary end point 
was pCR. pCR was observed in 41% of patients treated with T-DM1, 41.5% of patients 
treated with T-DM1 and ET, and 15.1% with trastuzumab and endocrine therapy (p<0.001). 
The ADAPT trial demonstrates that neoajuvant T-DM1 (with or without endocrine therapy) 
given for only 12 weeks results in a clinically meaningful pCR rate, thus a substantial number 
of patients might be spared the adverse effects of systemic chemotherapy.  
	
	
Figure 1.2 : Trastuzumab, Pertuzumab, Lapatinib: Mechanisms of action. 
Trastuzumab binds to the extracellular domain IV of HER2, thereby inhibiting ligand-independent HER2 
signalling. Pertuzumab binds to the extracellular domain II of HER2, inhibiting ligand-dependent HER2-
HER3 dimerization and signalling. Lapatinib binds to the cytoplasmic binding sites of the kinases and 






Endocrine therapy (ET) for breast cancer consists of 1) ovarian function suppression; 2) 
selective estrogen receptor modulators (SERMs); 3) selective estrogen receptor down-
regulators (SERDs); and 4) aromatase inhibitors (AIs), or a combination of 2 or more drugs. 
The 2 major strategies are directed at either blocking the estrogen receptors of cancer cells 
(SERMs), or by reducing estrogen production by acting against the key enzyme involved in 
its biosynthesis (AIs). 
1.7.1 Blocking Estrogen Function 
The SERMs include tamoxifen, raloxifene and toremifen. Tamoxifen is the most commonly 
used endocrine therapy and acts as an antiestrogen by inhibiting the binding of estrogen to 
estrogen receptors. It was initially studied as an anti-fertility drug, and soon demonstrated 
favourable effects in patients with ER+ breast cancer.222 Tamoxifen acts as a partial non-
steroidal agonist in some tissues, such as liver, uterus and bone, but is a competitive receptor 
inhibitor in the breast and brain.223 In these tissues, tamoxifen selectively blocks signalling at 
the level of ERs, also inhibiting the proliferation of ductal cells. It is hydroxylated by the 
cytochrome P450 enzyme system into 4-hydroxy tamoxifen (4HT), and further metabolised in 
the liver to endoxifen. Endoxifen and 4HT are the main active metabolites of tamoxifen and 
exhibit potent ER binding capacity and suppression of estrogen dependent cancer cells. The 
effects of tamoxifen binding are similar to that of estrogen, with dimerization causing a 
conformational change in the shape of the ER. However, rather than activating AF2, the 
tamoxifen bound receptor reduces or eliminates the activity of AF2. Consequently, the 
association of the ER with co-activator proteins does not take place, co-repressor proteins are 
not displaced and the transcription of estrogen-dependent genes is greatly reduced. Tamoxifen 
only benefits women with ER+ breast cancer, and ASCO (American Society of Clinical 
Oncology) guideline recommendations consider a cut off of 1% for IHC testing of ERs in 
breast cancer cells.224 This drug can be used in both pre and post menopausal breast cancer 
patients.  
SERMs have effects on other tissues containing ER, including bone, uterine and genitourinary 
tissues, the brain, and have an impact on cardiovascular risk. Whilst tamoxifen is an effective 
antagonist in the presence of high levels of estrogen, it can also exhibit some agonist activity 
on the breast and on other estrogen dependent tissues, particularly in the presence of low 
levels of estrogen. The estrogen agonist effects of tamoxifen in stimulating the endometrium 
have been well documented. Postmenopausal breast cancer patients treated with tamoxifen 
have increases in endometrial thickness and a high incidence of abnormal histopathological 
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findings in the endometrium.225, 226 A meta-analysis of breast cancer prevention trials found 
that tamoxifen therapy increases the risk of endometrial cancer by about 2.4 fold when 
compared with placebo.227 Furthermore, tamoxifen therapy was shown to increase the risk of 
thromboembolic events by 1.9 fold.  Another estrogen agonist effect of tamoxifen is that it 
helps to prevent bone demineralization in postmenopausal women, and can improve the lipid 
profile in these patients.  
In postmenopausal women, the ER signalling pathway may be targeted by fulvestrant 
(‘Faslodex’), a newer type of ER antagonist with no agonist effects. Fulvestrant, known as the 
‘pure anti-estrogen’, binds, blocks and causes degradation of the ER, culminating in complete 
suspension of estrogen-sensitive gene transcription. Clinical studies have demonstrated that 
fulvestrant is an effective treatment option in postmenopausal women with advanced breast 
cancer who have progressed on prior endocrine therapy.228 
1.7.2 Limiting Estrogen Production 
Aromatase Inhibition 
Aromatase, an enzyme of the cytochrome P-450 super family and the product of the CYP19 
gene, is expressed in several tissues, including subcutaneous fat, liver, muscle, brain, normal 
breast tissue, and mammary adenocarcinoma.229 It is responsible for the conversion of the 
adrenal androgen substrate androstenedione to estrogen in peripheral tissues (Figure 1.3),230 
and this is the predominant source of estrogen in postmenopausal women. Aromatase 
inhibitors (AIs) can reduce estrogen production by more than 90%.231,232 Unlike tamoxifen, 
however, AIs lack estrogen-agonist activity. Because AIs do not affect the ovarian production 













Figure 1.3: Mechanism of action of aromatase inhibitors. The adrenal androgen substrate. 
androstenedione is converted by aromatse to estrogen in the peripheral tissues. Aromatase inhibitors 




AIs are classified as first, second, or third generation according to the specificity and potency 
with which they inhibit the aromatase enzyme. They are further sub-classified as type 1 or 
type 2 inhibitors, according to the reversibility of their inhibitory activity. Type 1 inhibitors, 
steroidal analogues of androstenedione, irreversibly inhibit the aromatase enzyme by 
covalently binding to it. Permanent inactivation persists after discontinuation of the drug until 
the peripheral tissues synthesize new enzymes. In contrast, non-steroidal type 2 inhibitors 
bind reversibly to the aromatase enzyme, resulting in competitive inhibition233. Third 
generation AIs (i.e., anastrozole, letrozole, and exemestane) are the most potent, most 
selective, and least toxic AIs known today and can reduce serum estrogen by more than 95%.  
The AIs switch off peripheral estrogen biosynthesis almost completely and are highly 
effective in the treatment of postmenopausal breast cancer. Type 1 steroidal AIs 
(Exemestane) bind non-covalently and irreversibly to aromatase, whereas the type 2 steroidal 
AIs (Letrozole and Anastrozole) bind covalently and reversibly.234 Several clinical trials have 
evaluated the efficacy and safety of these agents. They are well tolerated and have become the 
endocrine therapy of choice in post-menopausal women with ER positive breast cancer. 
In pre-menopausal women AIs cannot be used in isolation for a number of reasons. Firstly, 
higher circulating levels of androgens present in premenopausal women compete with 
aromatase inhibitos for the aromatase enzyme complex, resulting in less efficient suppression 
of estrogen production. Secondly, hypothalamic/ pituitary feedback mechanisms in 
premenopausal women mean that lower serum estrogen levels lead to compensatory changes 
in the ovary, including upregulation of aromatase enzymes in the ovary, that render aromatase 
inhibitors ineffective.235 AI’s may be used as treatment in premenopausal women in special 
circumstances, such as prior tamoxifen failure or medical contraindications to tamoxifen. 
	
	 47	
When AIs are used in premenopausal women, they must be combined with surgical or 
medical ovarian ablation. There are several clinical studies evaluating the use of AIs in 
premenopausal women combined with ovarian suppression with a LH releasing hormone 
(LHRH) analogue. In 2003, the International Breast Cancer Study Group initiated two 
randomised trial, the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and 
Exemestane Trial (TEXT), involving premenopausal women with hormone-receptor-positive 
early breast cancer. The 5-year rates of recurrence of breast cancer were significantly lower 
among premenopausal women who received the aromatase inhibitor exemestane plus ovarian 
suppression than among those who received tamoxifen plus ovarian suppression.236,237  
 
1.7.3 Adjuvant Endocrine Therapy 
Historically, tamoxifen has been the standard treatment for hormone receptor-positive breast 
cancer, resulting in a significant improvement in disease-free survival (DFS) regardless of 
nodal status.238 For women with ER positive early breast cancer, treatment with tamoxifen for 
5 years substantially reduces the breast cancer mortality rate throughout the first 15 years 
after diagnosis. However, resistance to tamoxifen therapy in early breast cancer may occur as 
early as 12–18 months after the initiation of therapy.239 Therefore, the role of more effective, 
less toxic agents, such as the third-generation AIs, has been evaluated in adjuvant therapy for 
early breast cancer.  
Several adjuvant randomized studies of tamoxifen versus an AI as single agents or given in 
combination or sequentially have been conducted. 
Pre-menopausal Adjuvant Endocrine Therapy 
Ovarian function suppression (OFS) by GnRH agonists, ablation or radiotherapy is used in 
premenopausal patients to diminish the ovarian function in combination with tamoxifen or 
AIs. Five years of adjuvant treatment with tamoxifen versus no treatment has shown a relative 
risk reduction in 15 year recurrence risk of 40% with an absolute gain of 13.2%.240 The results 
of the TEXT and SOFT trials revealed that for premenopausal patients, addition of ovarian 
function suppression should be considered for patients younger than 35 years (5 year breast 
cancer free interval of 67.7% for tamoxifen vs 78.9% for tamoxifen plus OFS and 83.4% for 
exemestane plus OFS) or who received chemotherapy (5 year breast cancer free interval 78% 
for tamoxifen vs 82.5% for tamoxifen plus OFS vs 85.7% for exemestane plus OFS).241  
Extended Adjuvant Endocrine Therapy 
Despite the benefits of 5 years of tamoxifen, more than 50% of breast cancer relapses and 
more than two-thirds of deaths occur after the initial 5 years after surgery. More recent studies 
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have shown that a longer course of adjuvant endocrine therapy reduces the risk of breast 
cancer recurrence, breast cancer mortality and reduced overall mortality. The ATLAS 
(Adjuvant Tamoxifen: Longer Against Shorter) trial showed that continuation of tamoxifen to 
10 years rather than stopping at 5 years produces a further reduction in recurrence and 
mortality, particularly after year 10. The results of this trial taken with results from previous 
trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen 
treatment can approximately half breast cancer mortality during the second decade after 
diagnosis.242 
Furthermore, evidence in favour of extended AI therapy comes from the MA.17 Canadian 
trial. This trial showed that letrozole when given following five years of tamoxifen as 
extended adjuvant therapy, reduced the risk of local recurrence in ER positive, node negative 
patients. Patients with node positive disease had significantly improved overall survival with 
letrozole.243 For postmenopausal women with ER positive breast cancer, extended adjuvant 
therapy with letrozole has become the best standard of care.  
Current guidelines recommend 10 years of adjuvant endocrine therapy for the majority of pre- 
and postmenopausal patients who have ER positive disease. More recently the MA.17R trial 
was reported which studied the outcome of patients receiving up to 15 years of endocrine 
therapy, including 10 years of AI.244 Extension of AI treatment to 10 years resulted in 
significantly better 5-year DFS that included disease recurrence local/ distant or the 
occurrence of contralateral breast cancer events. No overall survival benefit was seen. Based 
on the results of the MA.17R trial, adjuvant treatment with 5 years tamoxifen followed by 10 
years of AI is considered appropriate for a specific subset of patients who have a high residual 
risk of late relapse. 
A recent meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) involved the results of 88 trials involving 62,923 women with ER positive breast 
cancer who received 5 years of endocrine therapy.127 The aim was to identify subgroups of 
women who stop endocrine therapy after 5 years in whom the long term risks of disease 
recurrence were so small that any additional benefits from extended therapy would be 
unlikely to outweigh the additional side effects. However, even among women with T1N0 
disease, the cumulative risk of distant recurrence was 13% during years 5 to 20. It was 
comcluded that breast cancer recurrences continued to occur steadily throughout the study 
period from 5 to 20 years. The risk of distant recurrence was strongly correclated with the 





1.7.4 Neoadjuvant Endocrine Therapy 
The aim of neoadjuvant endocrine therapy is to downstage disease either to allow surgical 
resection in otherwise inoperable tumours, or to allow breast conserving surgery for tumours 
that might otherwise have required a mastectomy. Such treatment is typically used for 
postmenopausal women with breast cancer. Few neoadjuvant endocrine studies have been 
conducted in premenopausal women.245 
In postmenopausal women with large, locally advanced, estrogen receptor rich breast cancers, 
neoadjuvant endocrine therapy is an appealing option as many older women may not be able 
to tolerate the toxicities of chemotherapy. In these women, neoadjuvant endocrine therapy can 
be used effectively to shrink tumours, rendering them amenable to breast conserving surgery, 
as opposed to mastectomy.  In tumours suitable for breast conserving surgery, neoadjuvant 
endocrine therapy can shrink the tumour so that a smaller surgical resection is required, 
allowing for improved cosmetic outcome.  Furthermore, patients with locally advanced breast 
cancer have a poorer prognosis than patients with early breast cancer, and whilst neoadjuvant 
treatment was initially dominated by chemotherapy, studies have shown response rates to 
neoadjuvant treatment with aromatase inhibitors in selected hormone receptor positive 
patients is comparable to that seen with neoadjuvant chemotherapy. 246 Women with locally 
advanced breast cancers may also benefit from endocrine therapy in terms of survival, and it 
allows women to avoid the more unpleasant toxicities associated with chemotherapy.  This is 
all the more important as hormone receptor positive tumours have repeatedly been shown to 
have lower response rates to neoadjuvant chemotherapy than hormone receptor negative 
tumours, in terms of pathological complete response.247,248,249  pCR rates of less than 15% have 
been reported with neoadjuvant anthracycline-taxane therapy in luminal-type breast cancer.238 
Because endocrine therapy has a different mechanism of action (focussed mainly on reducing 
the estrogen-induced effects on proliferation), pCR is rarely observed with endocrine 
therapy.250 However, it is possible that some clinical trials of only 3 months of neoadjuvant 
endocrine therapy, have underestimated the true pCR potential, given what may be a 
premature cessation of treatment. 251 It is often considered that assessment of pCR is a 
suitable surrogate endpoint for paitnets with HER2 positive (nonluminal) and triple negative 
breast cancer, less valid in those with luminal B (HER negative or positive) and probably not 
a good predictive test for patients with luminal A tumours.252 
Changes in tumour morphology and histology have been reported with neoadjuvant endocrine 
therapy and include decreases in cellularity, increases in fibrosis, so called ‘central scar 
formation’.253,254 Endocrine therapies do not appear to enhance tumour cell apoptosis and 
therefore apoptosis is not a useful predictor of benefit from therapy.   
	
	 50	
Whilst systemic treatment of HER2 positive disease has been dominated by chemotherapeutic 
agents, there is a need to explore whether the combination of HER2 targeted and endocrine 
therapy in this group of ER+/HER+ patients might firstly tackle the problem of endocrine 
resistance in these patients, and secondly, whether some of these patients might be treated 
safely and effectively with this combined therapy, and might avoid the need to use 
chemotherapy in these women.  
Several trials have assessed the efficacy and safety of neoadjuvant endocrine therapy using 
aromatase inhibitors in patients with postmenopausal breast cancer.255,256,257  In a randomised 
phase II study in which neoadjuvant endocrine therapy and neoadjuvant chemotherapy was 
compared in patients with hormone receptor positive breast cancer, no significant difference 
in the clinical response rate was observed between the two groups.258  Notably the rate of 
breast conserving surgery was numerically but not significantly higher and the incidence of 
most adverse events was lower in the endocrine therapy group compared with the 
chemotherapy group.  These results support the use of neoadjuvant endocrine therapy in 
postmenopausal patients with hormone sensitive breast cancer as an alternative to 
neoadjuvant chemotherapy. 
Currently, there is little data which allows one to identify which patients benefit from 
treatment with neoadjuvant endocrine therapy.  The Edinburgh Breast Unit has pioneered 
investigation of gene expression changes during neo-adjuvant treatment in so called ‘window 
of opportunity’ studies,258,259,260,261 and have published the first attempts to characterise the 
effects of the aromatase inhibitor, letrozole and the mTOR inhibitor, Everolimus on breast 
cancers261. The largest ‘window of opportunity’ neoadjuvant endocrine study, the 
PeriOperative Endocrine Therapy for Individualizing Care (POETIC) trial of 4,486 
postmeopausal patients with ER positive breast cancer who are randomised to nonsteroidal 
aromatase inhibitor or to no treatment for 2 weeks before and 2 weeks after surgery, has now 
completed recruitment in the UK. The primary endpoint is to assess whether endocrine 
therapy prior to surgery improves outcome and it is anticipated that the on treatment Ki67 
assessment may be of such significance that it could warrant its routine assessment.262  
The neoadjuvant setting allows prompt testing and evaluation of therapies and provides 
reliable results to inform and direct the design of adjuvant trials.  This approach is becoming 
increasingly important in the investigation of endocrine resistance, and can be used to look at 






Neoadjuvant Aromatase Inhibitor or Tamoxifen 
In the neoadjuvant setting, 4 phase III randomised clinical trials assessed whether an AI or 
tamoxifen should be given, three in postmenopausal and one in premenopausal women.  
Three trials of postmenopausal women were the P024 trial of letrozole vs tamoxifen before 
surgery,263 the IMPACT trial of anastrazole, tamoxifen, or a combination of tamoxifen and 
anastrozole for 12 weeks before surgery,264 and the PROACT trial of anastrozole vs 
tamoxifen.265 A meta-analysis of 3 studies, including 1160 patients, indicated superior 
outcomes in terms of clinical objective response rate, ultrasound response rate and breast 
conserving surgery rate with AI as compared to tamoxifen.191The STAGE trial of 197 
premenopausal women who were treated with neoadjuvant anastrozole or tamoxifen, both 
given in combination with goserelin, confirmed that anastrozole was superior to tamoxifen in 
terms of calliper response, ultrasonography response, and MRI or CT response. 266 Thereby, 
even though the role of neoadjuvant endocrine therapy in premenopausal women remains 
largely investigational, the results of the STAGE trial are consistent with the findings of other 
major adjuvant studies and it could be expected that the superior activity of neoadjuvant AI 
would translate into improved cancer outcomes with continued treatment in the adjuvant 
setting.   
 
Optimum Duration of Neoadjuvant Endocrine Therapy 
A three to four month duration has been proposed in the majority of the clinical trials such as 
P024,263 IMPACT264 and PROACT.265 However, there is evidence to suggest that three to four 
months duration could be insufficient to achieve maximum reduction in tumour volume. 
Dixon et al of the Edinburgh Breast Unit investigated the potential benefits of prolonged 
treatment with neoadjuvant letrozole in 182 patients.267 Of these, 63 patients were continued 
on letrozole beyond 3 months because of different reasons: 26 responded but not enough to 
allow breast conserving surgery, 15 responded but still had inoperable disease, 13 were unfit 
and considered unsuitable for surgery and 9 refused surgery. The response rate in the 182 
patients increased from 69.8% at 3 months to 83.5% after prolonged treatment, and 
importantly, breast conserving surgery increased from 60% to 72%. In another multicentre, 
prospective study of 146 patients with early BC, initially unsuitable for breast conserving 
surgery, treatment with letrozole was for a maximum of 12 months or until the patient became 
eligible for BCS, progressed or withdrew for scheduled mastectomy.268 The median time to 
achieve a tumour response sufficient to allow BCS was 7.5 months. Only 9 out of the 146 
patients had disease progression during neoadjuvant endocrine therapy. Until further data is 
available, the optimal duration of neoadjuvant endocrine therapy should be individualised 
based on careful and serial evaluation of clinical response. 
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Neoadjuvant Endocrine Therapy vs Neoadjuvant Chemotherapy 
There is limited evidence comparing neoadjuvant chemotherapy with neoadjuvant endocrine 
therapy. 2 randomised phase II trials have tried to address this question. In one trial of 239 
postmenopausal women were randomised to receive preoperative AI or chemotherapy, there 
was no significant difference between AI and chemotherapy in terms of clinical response rate, 
time to response, or pCR.269 Similarly, a second trial of exemestane or chemotherapy also 
found no significant difference between the 2 arms in terms of clinical response rate.270 The 
NEOCENT trial (neoadjuvant chemotherapy versus endocrine therapy), in postmenopausal 
women was prematurely closed because of slow accrual.271 Thus, clarity remains to be 





This thesis specifically relates to endocrine therapy in post-menopausal women, and as such 
the focus of the remainder of the introduction will be largely directed towards endocrine 
therapy. The relationship between estrogen and the breast is fundamental to the understanding 
of breast development, tumorigenesis and endocrine therapies for breast cancer.  Estrogens 
have been implicated in the development of breast cancer since Beatson discovered that 
oopherectomy prevented tumour recurrence and induced regression of breast cancers in the 
19th century.272 
1.8.1 Breast Development and Tumorigenesis 
The mammary gland is not completely formed at birth, but begins to develop in early puberty 
when the primitive ductal structures enlarge and branch. Once ovulatory menstrual cycles 
have begun, branching of the ductal system becomes more complex and lobular structures 
form at the ends of the terminal ducts to produce terminal ductal lobular units (TDLUs), 
which become more complex with successive menstrual cycles. During early pregnancy, 
there is another burst of activity in which the ductal trees expand further and the number of 
ductules within the TDLUs increases greatly. These ductules differentiate to synthesise and 
secrete milk in late pregnancy and subsequent lactation. Histological studies have shown that 
most human breast tumours appear to be derived from TDLUs and have morphological 
characteristics of luminal epithelial cells. Human tumours also contain receptors for estradiol 
and progesterone that, in the normal breast, are expressed only in the luminal epithelial cell 
compartment. 273 
The clinical and epidemiological evidence for the role of estrogen in human mammary gland 
development and tumorigenesis is considerable. There is complete failure of breast 
development in the absence of intact ovarian function, and estradiol-replacement therapy is 
necessary to induce breast development.274 Increased exposure to the fluctuating levels of 
estradiol of the menstrual cycle through early menarche, late menopause or a late, first, full-
term pregnancy increases breast cancer risk, as does use of exogenous estrogens in the form 
of the oral contraceptive pill or hormone replacement therapy.275More compellingly, 
treatment with anti-estrogens reduces the incidence of breast cancer in high-risk women. 
There is less evidence for a role of progesterone in human breast development. Studies on 
mouse models in which the PR has been knocked out suggest that, whereas estradiol 
stimulates ductal elongation and PR expression, progesterone induces lobulo-alveolar 
development.276 As far the role of progesterone in breast tumorigenesis is concerned, there is 
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data to suggest that exogenous progestins taken in the form of combined hormone 
replacement therapy increase the risk of postmenopausal breast cancer to a greater extent than 
use of estrogen replacement therapy alone.277 
1.8.2 Estrogen Production 
The estrogens are a family of steroid hormones that stimulate the development and 
maintenance of female secondary sexual characteristics and sexual reproduction. The most 
prevalent forms of circulating estrogens are estradiol and oestrone, but their primary site of 
production differs according to menopausal status. In pre-menopausal women the ovaries are 
the primary source of estrogen production, with small amounts produced by the adrenal 
cortex and other organs. In postmenopausal women, with declining ovarian function, estrogen 
production occurs predominantly by the peripheral conversion of ovarian and adrenal 
androgens to estrogen in peripheral muscle and bone as well as within breast tumours. This 
conversion is a function of the aromatase enzyme, a product of the CYP-19 gene of 
chromosome 15.278 
1.8.3 The Estrogen and Progesterone Receptors 
The steroid hormones estradiol and progesterone are lipophilic, they enter the cell nucleus 
primarily by diffusing through the plasma and nuclear membranes. Once in the nucleus, the 
steroids encounter proteins known as receptors and they bind their ligands with high affinity 
and specificity. There are two receptors for estradiol, the ERα and the ERβ. Both these ERs 
are members of the steroid/thyroid hormone nuclear receptor superfamily and both may be 
described as ligand-dependent nuclear transcription factors.273 It is likely that ERα is the key 
mediator of estrogen in the normal mammary gland and that ERβ mediates some of the non-
classical effects of the estrogens and may even negatively modulate the activity of ERα. 
Progesterone also has two receptors, PRA and PRB. They are also members of the 
steroid/thyroid hormone nuclear receptor superfamily, and they function as ligand dependent 
nuclear transcription factors. It has been suggested that PRB is the major activator of gene 
transcription and that PRA is a repressor of PRB activity.279 
Most data on ER and PR expression in the normal human breast have been obtained in the 
course of studies on tissue from adult women who are not pregnant or lactating. These studies 
show that ERα is expressed in approximately 15–30% of luminal epithelial cells and not at all 
in any of the other cell types within the human breast.280 Initial studies indicate that the ERβ 
is expressed in most luminal epithelial and myoepithelial cells, as well as being detectable in 
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fibroblasts and other stromal cells within the normal human breast.281 The PR is thought to be 
present in 15-30% of luminal epithelial cells and not elsewhere in the breast.  
1.8.4 Estrogen Receptor Signalling  
Once inside the cell nucleus, steroid hormones bind to their respective receptors with high 
affinity and specificity. This is known as the ‘classical estrogen signalling pathway’ (Figure 
1.4). In the absence of this highly specific binding, the receptors are inactive and exist in a 
monomeric form bound to heat shock proteins such that they exert no influence on a cells 
DNA expression. However, upon binding, the ER dissociates from its heat shock protein and 
undergoes a process of homo-dimerization and protein phosphorylation on a number of 
specific residues. This leads to conformational change in the shape of the AF2 region. 
Consequently, the ER dimers bind to specific DNA sites, known as estrogen response 
elements (EREs). These consist of palindromic nucleotide sequences and they lie upstream of 
estrogen responsive genes. The ER dimers simultaneously associate themselves with receptor 
co-activator proteins and together these associations are responsible for the activation of a 
large number of estrogen dependent genes, the transcription of their messenger RNA 
(mRNA) and the subsequent translation of this mRNA into proteins which invariably impact 
on the properties of the cell, the cell cycle and that of their adjacent cells.282 
Additional estrogen signalling pathways have been described. It has been suggested that the 
estrogen receptor may bind to and activate the activity of 2 further transcription factors, jun 
and fos, which may recognise alternative receptor binding sites and perpetuate cell 
proliferation signalling. Another suggestion is that estrogen receptors within the plasma 
membrane may participate in the activation of growth factor receptor signalling, by activating 
the ER1/2 gene, and thus influencing the nearby activity of dividing cells via protein kinase 
signalling pathways.  
In many neoplastic breast cells, the ER signalling network contributes to controlling the 
relative rates of cell proliferation and programmed cell death, with pro-survival and 
proliferation signals overwhelming pro-death and quiescence signals. To make substantial 
new advances in the treatment of advanced breast cancer, we need a better understanding of 
the ER signalling network. Studies have shown the functional relevance of several factors 
involved in ER signalling, including nuclear factor κB (NF-κB), a pro-survival transcription 
factor that is highly expressed in hormone resistant cells compared to hormone sensitive 
cells,283 interferon regulatory factor 1 (IRF1),284 a pro-death transcription factor that is down 
regulated in endocrine-resistant cells, and X-box binding protein 1 (XBP1), a transcription 
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factor that is involved in the unfolded protein response (UPR) and the induction of autophagy 








Whilst the ER negative/ HER2 positive subtype of breast cancers is a relatively well 
characterised group in terms of tumour biology and behaviour, the ER positive/ HER2 
positive (ER+/HER2+) subtype has been less well investigated.  HER2 positive cancers 
account for 15-20% of all breast cancers and 50% of these are ER positive.  The ER+/HER2+ 
molecular subtype accounts for up to 10% of all breast cancers, and is an important subset 
because even small HER2 positive cancers have a much worse prognosis than similar sized 
ER+/HER2 negative cancers. There is now considerable pre-clinical and clinical evidence 
demonstrating that ER+/HER2+ tumours exhibit both intrinsic and acquired resistance to 
endocrine therapy.  This is pertinent as endocrine therapy to block ER activity and signalling, 
remains at the forefront of systemic treatment for all women with ER positive disease.  It is 
unclear as to whether ER signalling or HER2 signalling drives resistance to endocrine therapy 
in the ER+/HER2+ subset. 
Resistance to endocrine therapy, both primary and acquired, is a major clinical problem in the 
management of hormone receptor positive breast cancers. Extra tumoural mechanisms of 
resistance include patient factors, such as poor compliance with treatment and adverse drug 
metabolism reducing the levels of active drug metabolites. More specific mechanisms of 
resistance include 1) Loss or reduction of ER expression; 2) ER mutations leading to 
desensitisation to ER targeted therapies; 3) HER2 overexpression; 4) Activation of redundant 
pathways bypassing the need for ER.  Mechanisms of endocrine resistance will be discussed 
specifically with regard to the ER+/ HER2+ subtype. 
1.9.1 ER/ HER2 Crosstalk 
Both the ER and HER receptor pathways play important roles in driving growth and 
proliferation of breast cancers.  It is evident that there exists crosstalk between ER and the 
EGFR/HER2 pathway and that this plays an important role not only in the physiological 
action of ER as part of growth factor receptor signalling, but also plays an important role in 
endocrine resistance.  There are different biological mechanisms which may explain how 
HER2 signalling could result in endocrine resistance.  HER2 signalling may impair endocrine 
sensitivity by increasing ERα function, either directly by phosphorylating and activating the 
AF-1 domain of the receptor (at Ser167 or Ser118), or indirectly by recruiting coactivators to 
ERα, which leads to increased ERα transcriptional activity.286,287,288 Another possible 
mechanism is via signalling through membrane receptors and downstream effectors such as 
extracellular signal-regulated kinase (ERK) which can suppress ERα expression and function, 
thereby promoting ERα independence. Alternatively, conversion to an ER negative phenotype 
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will result in endocrine resistance.289,290,291,292 While membrane ER can activate HER2 
signalling, the kinase cascade downstream of HER2 can phosphorylate and activate ER and 
its co-regulatory proteins.  This pathway interaction was first implicated when it was noted 
that transfection of ER+ breast cancer cells with HER2 resulted in down-regulation of ER and 
resistance to tamoxifen.293 These were the first studies to implicate ER/HER2 crosstalk as 
important in primary endocrine resistance. Later studies have subsequently demonstrated and 
confirmed its role in acquired endocrine resistance.  Tamoxifen treated breast cancer cells in 
long-term culture have been reported to show increased levels of expression of EGFR and 
HER2, increased activation of EGFR/HER2 heterodimers, and increased phosphorylation of 
p42/44 MAPK, AKT and nuclear ER.294,295 These findings indicate that enhanced growth 
factor signalling, can up-regulate both the genomic and non-genomic activities of ER, which 
could be a key contributor to at least one mechanism of acquired endocrine resistance. 
Crosstalk between ER and HER2 signalling pathways may not only play a role in resistance 
to endocrine therapy, but also in resistance to HER2 targeted agents.245  
1.9.2 HER2 ‘escape/ survival’ route 
The human epidermal growth factor receptor family (HER) family comprises four 
homologous transmembrane receptors (HER1, also known as EGFR, HER2, HER3 and 
HER4), which form a complex system of growth factors involved in growth regulation.203 As 
a result of ligand binding, HER receptors form a series of dimers that result in 
autophosphorylation, with activation of tyrosine kinases and downstream signalling 
pathways. Overexpression of HER2 leads to transformation in the absence of a ligand.  None 
of the HER family of ligands binds to HER2 directly.  Therefore, HER2 is regarded as an 
orphan receptor.  It appears that HER2 is the preferred dimerization partner for all other HER 
receptors, and as such HER2 functions as a shared co-receptor.  Indeed, both HER1 and 
HER3 have been shown to be upregulated in breast cancers with HER2 overexpression.296 
HER2 has been demonstrated to play a role in both primary and acquired resistance to 
endocrine therapy.  A meta-analysis on the interaction between response to endocrine 
treatment and over expression of HER2 in metastatic breast cancer concluded that HER2 
positive metastatic breast cancer is less responsive to any type of endocrine treatment. 
 
Three trials have shown in the metastatic setting that the combination of an aromatase 
inhibitor with an anti-HER2 agent is superior to aromatase inhibitor alone as first line therapy 
in patients with HER2 positive and ER positive disease, in terms of progression free survival.  
The randomised phase III TANDEM trial included 207 patients with HER2 positive, ER 
positive metastatic breast cancer demonstrated a doubling of progression free survival time 
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with the addition of trastuzumab to anastrozole versus anastrozole alone (4.8 vs 2.4 
months).297 Johnston et al also showed a significantly increased progression free survival (8.2 
vs 3 months) for a combination of letrozole plus lapatinib compared with letrozole alone in a 
randomised phase III first line trial in HER2 positive disease.  The PFS rate in the AI alone 
arm indicates that endocrine therapy alone may not be sufficiently effective in triple positive 
disease.298 In the eLEcTRA study, women with ER positive/ HER2 positive disease were 
randomised to receive either letrozole monotherapy or letrozole plus trastuzumab as first line 
treatment.  Median time to progression was 3.3 months in patients who received letrozole 
alone, and 14.1 months in the combined therapy arm.  In patients with HER2 negative disease 
who received letrozole monotherapy, median time to progression was 15.2 months.299 
Importantly, these 3 studies provide support the view that carefully selected ER+/HER2+ 
cancers can be effectively treated with combined endocrine and HER2 targeted therapies, 
without the need for chemotherapy.   
Response rates to aromatase inhibitors range between 35% and 70% in neoadjuvant studies, 
and benefits may be lower in advanced disease.255,264 Acquired resistance after initial 
successful treatment also occurs and it seems that HER2 signalling may play an important 
role in this acquired resistance to endocrine therapy.300  In the group of patients with ER 
positive cancers who do develop resistance, it may not be adequate to treat their disease with 
second-line anti-estrogen therapy alone.  In one in vitro study of human breast cancer cells, 
modest adaptive increases in HER2 expression occurred in 20% of patients who relapsed on 
tamoxifen.  In cell models of ER+/HER2- breast cancers, with acquired endocrine resistance 
and modest adaptive increases in HER2, the combination of lapatinib and endocrine therapy 
resulted in synergistic growth inhibition.301  These cells did not achieve HER2 levels 
comparable with HER2 amplified breast cancers, and indeed in clinical practice conversion 
from HER2 negative to HER2 2+/3+ FISH positivity remains a rare event.  What these results 
suggest is that even with a modest increase in HER2 expression, crosstalk between the HER2 
and ER pathways can develop and may be important in resistance to endocrine therapies.  In 
other studies, trastuzumab has been shown to inhibit growth of endocrine resistant ER 
positive breast cancers which have increased HER2 protein expression, but are not HER2 
amplified.302,303 The combination of lapatinib and letrozole has also been shown to be 
effective in some endocrine resistant, HER2 negative metastatic breast cancers.298 HER2 
expression in some patients is higher in metastatic cancers compared with primary disease.  
Given the plasticity of endocrine resistance in breast cancers, treatment strategies should be 
based on the phenotype of the tumour at relapse rather than that at diagnosis. 
Unfortunately, there is limited available information on the use of combined endocrine 
therapy and anti-HER2 therapy in the non-metastatic setting.  The current observations 
suggest that HER2 does play an important role in primary endocrine resistance.  Furthermore, 
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studies lead us to question the effectiveness of endocrine therapy alone in some patients with 
ER+/HER+ breast cancers and it is almost certain that a proportion would benefit from the 
addition of a HER2 targeted agent.    
 
1.9.3 ER ‘escape/survival route’ 
In the same way that HER2 signalling can provide an ‘escape route’ to endocrine therapy in 
ER positive patients, ER signalling can provide an ‘escape route’ in patients treated with anti-
HER2 therapy who do not get total ER blockade.  In an in vitro study of HER2 resistant cell 
lines ER+/HER2+ cells were shown to exploit ER activity as a mechanism of primary and 
acquired resistance.  In ER+/HER2+ tumours, whilst either ER or HER2 may initially 
function as the driver of proliferation and survival, with sustained, effective HER2 inhibition 
with lapatinib, or lapatinib plus trastuzumab, ER will eventually become the primary driver of 
cell survival, resulting in resistance to anti-HER2 therapy.304 These findings are consistent 
with results from several neoadjuvant clinical trials investigating HER2 targeted agents with 
or without chemotherapy in patients with early HER2+ breast cancers.  Whilst the results 
differed between trials depending on the type of HER2 targeted agents and chemotherapy 
used, there is a consistently lower pCR in ER+/ HER2+ cancers, compared with ER-/ HER2+ 
cancers. In the clinical NeoSphere and NeoALLTO trials, patients with HER2 positive 
disease received neoadjuvant chemotherapy in addition to HER2 targeted therapy, but no ER 
targeted therapy.219,220 There was a significantly lower pCR in ER+/HER2+ in both trials 
compared with ER-/HER2+ tumours.  The NeoSphere trial combined docetaxel with 
trastuzumab alone, pertuzumab alone, or trastuzumab plus pertuzumab, and also included an 
arm without chemotherapy (trastuzumab and pertuzumab only).  In this latter arm there was a 
5.9% pCR rate in ER/PR positive tumours treated only with trastuzumab and pertuzumab 
compared with 29.1% in the ER/PR negative group.  This demonstrates the importance of 
blocking the ER pathway in ER+/HER2+ cancers and supports the efficacy of the 
trastuzumab/ pertuzumab combination in ER/PR negative cancers.  In a further phase II 
multicenter study, neoadjuvant lapatinib and trastuzumab was given to patients with HER2 
and ER positive disease, combined with letrozole.  The pCR rate in patients with ER positive 
disease was 21%.305 Neoadjuvant treatment of patients with ER-/HER2+ breast cancers with 
combined trastuzumab and chemotherapy has been shown to change ER status from negative 
to positive in up to 20% of cases.  This suggests that blocking HER2 signalling might result in 
an up regulation of ER and ER transcriptional activity, allowing for an ER driven escape 
route.306 Taken together, these studies highlight the importance of providing blockade of both 




The ER+/HER2+ subtype accounts for up to 10% of all breast cancers and is an important 
subtype as these cancers have a worse prognosis than ER+/HER2- breast cancers. While there 
is now considerable preclinical and clinical evidence that ER+/HER2+ cancers exhibit 
intrinsic and acquired resistance to endocrine therapy, it remains unclear what is driving this 
resistance to therapy. This is a pressing clinical issue as endocrine therapy remains at the 
forefront of systemic treatment for all women with ER+ disease. However, many patients 
with ER+/HER2+ disease do respond well to endocrine therapy. The challenge, therefore, is 
in identifying, early in the process of treatment decision-making, who will respond to 
endocrine therapy and who might benefit from combined endocrine and HER2-targeted 
agents, or HER2-targeted agents alone. 
Neoadjuvant therapy with third-generation aromatase inhibitors such as letrozole and 
anastrozole have an established role in the treatment of estrogen-receptor alpha positive 
postmenopausal breast cancer. This neoadjuvant approach can result in downsizing of large, 
locally advanced tumours allowing for increased rates of breast conserving surgery and 
curative resections.  Furthermore, neoadjuvant therapy affords the use of ‘window of 
opportunity studies’ where tumour biopsies taken before treatment onset, during the treatment 
and ultimately from the surgical excision.  Not only can response to treatment be monitored 
biologically and clinically, this approach improves statistical power by reducing patient-
patient variation. However, these studies are typically difficult to perform owing to the 
demands of effective tissue collection and storage and are largely dependent on patient and 











2. Aims and Objectives	
There is considerable preclinical and clinical evidence that ER positive/ HER2 positive 
tumours exhibit resistance to endocrine therapy. This is a pressing clinical issue as endocrine 
therapy remains at the forefront of systemic treatment for all women with ER positive 
disease. However, many patients with ER+/ HER2+ disease will respond well to endocrine 
therapy. The challenge therefore, is in identifying, early in the treatment process, who will 
respond to endocrine therapy, and who might benefit from combined endocrine and HER2 
targeted agents.  
The current study uses the largest data set of matched ER positive/ HER2 positive breast 
cancer samples before and during endocrine treatment.  The aims of this study are: 
1. To investigate which ER positive/ HER2 positive breast cancers respond to letrozole. 
2. To compare the mechanisms of resistance to endocrine therapy in ER+/ HER2+ and 
ER+ / HER2- breast cancers. 
3. To determine which cancers should be considered for combined endocrine and anti-





3. Materials and Methods	
3.1 Study Design	
This study involved the prospective enrolment of postmenopausal patients presenting with 
locally advanced or large operable, ER positive breast cancer for whom the current clinical 
guidelines suggest neoadjuvant treatment with the aromatase inhibitor Letrozole.	
All patients included in the study were diagnosed and treated at the Edinburgh Breast Unit, 
Western General Hospital. Patients who met the eligibility criteria were discussed at a weekly 
multi disciplinary meeting (MDM) and referred to a member of the medical or research staff 
involved. Patients were provided with detailed written information about the study design and 
a meeting was arranged for patients to discuss this further. All patients gave informed consent 
and the study was approved by the local regional ethics committee (2001/8/80 and 2001/8/81; 
Appendix 1). The patients general practitioner was sent information about the study and the 
patients enrolment. 	
Of note is that several studies were undertaken simultaneously to maximise the research 
potential of the information and tissue samples collected from the respective patients. The 
extended conduct and findings of further studies are out with the scope of this thesis. 	
Letrozole (Femara; Novartis Pharmaceuticals AG, Basel, Switzerland) is a reversible, non-
steroidal aromatase inhibitor. It is licensed in the UK for the adjuvant treatment of 
postmenopausal women with hormone-receptor-positive invasive early breast cancer, and for 
the treatment of postmenopausal women with hormone-receptor-positive invasive early breast 
cancer who have already received standard adjuvant tamoxifen therapy for 5 years. Letrozole 
is also licensed in the UK for various indications in advanced breast cancer and as neo-
adjuvant treatment.339 Patients were treated with a neoadjuvant protocol in which letrozole 
2.5mg was given daily for at least 3 months.	
3.2 Patients 
A consecutive series of 255 postmenopausal women presenting to the Edinburgh Breast Unit 
(Western General Hospital) with large primary histologically confirmed invasive breast 
cancer, immunohistochemically (IHC) determined to be estrogen receptor (ER) positive 
(Allred score≥6) were recruited between 2003 and 2011. Patients were excluded based on 
strict predefined criteria: (i) if the tumour was multifocal, (ii) if histological assessment by a 
pathologist determined low cellularity or less than 40% malignancy, (iii) if extraction failed to 
yield sufficiently good quality RNA to be suitable for further study, (iv) if follow-up records 
for clinical assessment of response were unavailable or incomplete, (v) if less than two 
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tumour biopsies were available or carried out, including a before-treatment biopsy, or (vi) if 
the drug was changed from letrozole to another agent during the 3 month treatment window 
due to an adverse drug reaction.  
Of the patients who met the predefined criteria, 17 were classified as ER positive/ HER2 
positive at diagnosis and had 3 or more tumour biopsies available (comprising pre-treatment, 
14 day and approximately 3 month biopsies) and were selected for microarray analysis. A 
patient was determined to be HER2+ with an IHC score of 3; or IHC 2+ and FISH positive.  
3.3 Tumour Samples 
Tumour biopsies were taken with a 14-guage needle: before, and approximately 14 days and 
3 months following commencement of continuous letrozole treatment (Figure 4.1A). Samples 
were snap-frozen in liquid nitrogen and frozen sections taken, stained with haematoxylin and 
eosin (H&E) and the cellularity and percentage presence of cancerous tissue within each 
specimen was assessed by a pathologist.  
3.4 Assessment of Response 
Clinical response was determined using dynamic changes in tumour volumes assessed by 
repeated measurements taken over the 3 month treatment period. Primary assessment was 
based on ultrasound measurements performed by a single observer (JMD) and these were 
verified by mammographic measurements. Clinical response was reassessed for samples 
using strict predefined criteria. In order to be consistent with the validation dataset, we also 
classified response independently using the modified International Union Against Cancer 
IUAC/WHO criteria. As a secondary endpoint, pathological response was determined from 
the clinical records, originally assessed by a pathologist. 
3.5 RNA Processing and Microarray Hybridisation 
Biopsies were homogenised and RNA was extracted using the RNeasy Mini Kit with RNAse-
free DNAse treatment (Qiagen). RNA quantity and quality was verified on a Bioanalyser 
2100 with RNA 6000 Nano Kit (Agilent) and Nanodrop 2000c (Thermo Scientific). RNA was 
reverse transcribed and amplified using the WT-Ovation FFPE System Version 2 (NuGEN), 
purified using the Qiaquick PCR Purification Kit (Qiagen), biotinylated using the IL Encore 
Biotin Module (NuGEN), purified using minElute Reaction Cleanup Kit (Qiagen) and 
quantified once again using the Nanodrop 2000c (Thermo Scientific). Labelled cDNA was 
hybridised to Human HT-12v4 whole-genome expression beadarrays (Illumina) according to 
the standard protocol for NuGEN amplified samples.  Samples in the same response group 
were assigned random positions across all the Beadarrays with samples from the same patient 
	
	 65	
on the same array. Beadarrays were hybridised and processed in 5 batches and each batch 
included a replicate Universal Human Reference RNA(UHRR) control sample in order to 
assess the need for batch effect correction. The Human HT-12v4 whole-genome expression 
Beadarray covers more than 48000 transcript probes and its annotation is publically available. 
Raw gene expression files are publicly available from the caBIG supported Edinburgh 
Clinical Research Facility Data Repository (https://catissuesuite.ecmc.ed.ac.uk/caarray/). 
Data were extracted using the GenomeStudio software (Illumina). 
3.6. Affymetrix Dataset 
Affymetrix gene expression data was generated from primary breast tumour tissue biopsies 
taken before, approximately 14 days after and again approximately 3 months after 
commencement of continuous neoadjuvant letrozole treatment in 58 patients (data was 
available online from 55 patients) as part of a previously described clinical study.340,341 
Patients were selected from a consecutive series recruited between 2001 and 2003 as part of 
the aforementioned letrozole clinical audit.  RNA was extracted, amplified and labelled as 
previously described before hybridisation to HGU-133A GeneChips (Affymetrix) according 
to the standard protocol. 
3.7 Data Processing and Analysis 
All data was processed using the R/Bioconductor software and packages, and the TM4 
Microarray software suite (MeV). Data generated on the Illumina microarray platform (this 
study, samples from 34 patients) and data generated on the Affymetrix platform (published 
dataset340,341 samples from 45 patients) were each independently pre-processed and re-
annotated to Ensembl gene identifiers, then combined and batch corrected.296 UHRR control 
samples were removed from the Illumina dataset prior to pre-processing. Illumina probe 
profiles were quantile normalised using the lumi package (R/Bioconductor) and mapped to 
Ensembl gene sequences using a composite list comprising mappings from reMOAT, 
Ensembl BioMart and a custom BLAST sequence search of the online Ensembl gene database 
where there was agreement between at least two of the resources. Where multiple Illumina 
probes represented an Ensembl gene, the mean expression level was calculated. A custom 
Chip Definition File (CDF)297 was used to map the Affymetrix data to Ensembl gene 
annotations and RMA implemented by the affy package (R/Bioconductor) was used for 
normalisation. The datasets were then filtered using Illumina or Affymetrix probe detection 
P-values, removing probes that were undetected (P>0.05 in the total minus 3 samples). Both 
datasets were then combined and batch-corrected with cross-platform normalisation (XPN; 
ArrayMining) to reduce platform associated bias. The combined, corrected Affymetrix and 
Illumina dataset (79 patients; 237 samples) was used for all further analysis. These datasets 
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were considered suitable for integration as both studies were designed with a similar 
experimental focus and both studies have similar composition in terms of patient/sample 
numbers and clinical parameters.  
Differential gene expression analysis was performed using Rank Product and Significance 
Analysis of Microarrays (MeV; TM4 Microarray Software Suite). Pathway enrichment 
analysis was performed in DAVID Bioinformatics Resources 6.7 using the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG).298 The most informative features 
differentiating between responders and non-responders were identified using Random Forest 
(RF) (Salford Predictive Miner, Salford Systems, San Diego, USA) and predictive signatures 
were assessed using Support Vector Machines (SVM;e1071 package), centroid classification 
and logistic regression (glmpackage). Gene expression heat-maps were generated in MeV 
using Euclidean distance with complete linkage following gene mean-centering performed in 
Cluster 3.0.343 Multidimensional scaling was performed in R with 3D scaling plots generated 
in JMP10 (JMP Software, USA). Statistical analyses were carried out in Prism 6 (Graphpad 
Software, California, USA). 
3.8 Immunohistochemistry 
Formalin-fixed, paraffin embedded sections were stained with rabbit antibodies to ERK-
p44/42 MAPK (#9102) Cell Signalling, 1:200; and pERK-P-p44/42 MAPK (#9101) Cell 
Signalling, 1:25. Antigen retrieval was carried out with  0.1M sodium citrate/0.1M citric acid 
pH6 and detection using the EnVision TM kit (Dako, Agilent Technologies) as per the 
manufacturer’s standard protocol (Table 3.1).  
Protein expression was assessed by 2 independent scores, blinded to clinical response. Images 
were interpreted visually using the ‘NDP.view2’ software. Semi-quantative protein 
expression was determined on staining intensity and scored ‘High’, ‘Intermediate’ or ‘Low’. 
The available patient tissue is highly valued and as such breast cancer mouse xenograft tissue 












3.9 Validation with treatment naïve ER+/ HER2+ cohort	
Affymetrix gene expression data was generated from primary breast tumour tissue biopsies 
taken from surgical resection specimens of 13 tumours identified as being ER+/ HER2+ by 
standard classification. RNA was extracted, amplified and labelled as previously described 




Appropriate treatment with the available anti-HER2 therapies depends on prompt assessment 
of HER2 status on all patients with invasive breast carcinoma at diagnosis. All invasive breast 
cancers are tested for the presence of HER2 overexpression. The method most widely used is 
an immunohistochemical assay which classifies HER2 on a subjective scale of 0, 1+, 2+, and 
3+.  Patients with 0 and 1+ are considered to have low expression and to be HER2 negative. 
Patients with 2+ are considered indeterminate and those with 3+ are considered to be HER2 
positive. This IHC assay is about 90% accurate.278 Various in situ hybridisation techniques, 
which use one or two tags for the centromere on chromosome 17 and the HER2 gene, are also 
available.274, 275 If the ratio of HER2 to the centromere on chromosome 17 is greater than 2.2 
then HER2 is considered to be amplified.278 These tests are performed on tumour samples that 


































































A survey of UK surgeons was performed to determine how many breast units had readily 
available access to HER2 assessment, and in particular how many units had HER2 results 
available in time for the post operative multidisciplinary meeting, when decisions are made 
on adjuvant treatment. A questionnaire was sent to 220 breast units throughout the UK, 187 




4.1 Patient Numbers and Clinical Response  
Of the 76 patients studied, a total of 17 were ER+/ HER2+ at diagnosis and tissue biopsies 
and tumour volume measurements at baseline, 14 days and 3 months was available for each 
of these. Response to neoadjuvant letrozole therapy was defined as a volume reduction of at 
least 50% by 45 days and 70% by 3 months. Non response was defined as a volume increase 

















 Figure 4.1A: Fresh frozen biopsy and initial tumour volume by 3D USS at baseline. Neoadjuvant letrozole therapy commenced, interval biopsy and USS at 14 days and 3 months. Microarray data 
generated from baseline, 14 day and 3 month samples. Patients divided into Responders or Non 





Of the 17 ER+/HER2+ patients, almost half (8/17; 47%) were responders (R) to neoadjuvant 
letrozole, and the others (9/17; 53%) were non responders (NR) to neoadjuvant letrozole 
therapy (Figures 4.1B).   
This group of ER+/ HER2+ patients was compared with 59 patients who were ER+/ HER2 
negative (ER+/ HER2-). Of these, 48 (81.%) were responders (R) to neoadjuvant letrozole 
therapy and 11 (19%) were non responders (NR) to neoadjuvant letrozole therapy, based on 
the same clinical response criteria. 
Overall, just over half of the patients in the ER+/HER2+ subgroup (9/17; 53%) did not 
respond to neoadjuvant letrozole therapy, a much larger proportion compared with 19% 











4.2 ERBB2 Expression at Baseline 
The level of expression of the HER2 gene (ERBB2) was significantly higher at baseline in the 
ER+/ HER2+ NR group of patients than in any of the other subgroups.  
Expression of ERBB2 at baseline in ER+/ HER2+ Non Responders was significantly higher 
than in ER+/ HER2+ Responders (p=0.005). 
Less surprisingly, the baseline expression of ERBB2 was also significantly higher than in both 




Figure 4.2: Baseline expression of ERBB2. ER+/ HER2+ Non Responding subgroup 
has a significantly higher baseline expression of ERBB2 than ER+/ HER2+ 






4.3 ERBB2 Expression in ER Positive/ HER2 Negative Groups 
The expression level of ERBB2 was almost the same at baseline in both the ER+/ HER2- 
Responding and Non Responding subgroups. However, in the ER+/HER2 – Non Responding 
group, expression of ERBB2 increased over the 3 month neoadjuvant letrozole treatment 
period and at 3 months was significantly higher in the ER+/ HER2- Non Responding group 
than in the ER+/ HER2- Responding group (p=0.015). This might suggest that even in HER2 




Figure 4.3: Change in level of expression of ERBB2 over 3 month neoadjuvant letrozole. 
At 3 months ERBB2 expression in ER+/ HER2- Non Responders is significantly higher 





4.4 Estrogen Signalling 
Whilst all of the patients included in the study had ER rich tumours (Allred score between 6-
8), there were significant variations seen in the expression of ESR1 before neoadjuvant 
letrozole treatment started.  
The expression level of the ESR1 gene was significantly lower at baseline in the ER+/ HER2+ 
Non Responding group than in all the other subgroups including ER+/ HER2+ Responders 
(p=0.0003); ER+/ HER2- Responders (p=0.0007); and ER+/ HER2- Non Responders 
(p=0.009) (Figure 4.4A). 
 
 
This evidence suggests that even before treatment with neoadjuvant letrozole commences, the 
ER+/ HER2+ Non Responding subgroup is different in terms of estrogenic signalling 
pathways, and would support the hypothesis that this group of patients who do not respond to 





Figure 4.4A: Baseline expression of ESR1. ER+/ HER2+ Non Responding subgroup has a 
significantly lower baseline expression of ESR1 than ER+/ HER2+ Responders (p=0.0003); 







Using a set of genes known to be involved in estrogen signalling, differences were noted in 
the expression levels between the subgroups.330 The estrogen signalling genes analysed were: 
ESR1; ESR2; PGR; GATA3; FOXA1; AGR2; NAT1; and BCL2. 
At baseline, the mean expression level of these genes was significantly higher in the ER+/ 
HER2+ Responding group than in the ER+/HER2+ Non Responding group (p=0.005) (Figure 
4.4B).  
During the 3 month neoadjuvant letrozole treatment period, the value of expression of these 
estrogen signalling genes fell dramatically in the ER+/ HER2+ Responding subgroup, in 
keeping with the anti-estrogenic effects of letrozole in this clinically responding group 
(Figure 4.4B).  
In the ER+/ HER2+ Non Responding subgroup, the level of expression of these estrogen 
signalling genes fell during the first 14 days of treatment with neoadjuvant letrozole but 
thereafter, between the 14 days and the 3 months periods, there was virtually no further 
change in the expression of these genes. This would suggest that after the initial 14 days the 
anti-estrogenic effects of letrozole had no effect on this clinically Non Responding ER+/ 
HER2+ group of patients (Figure 4.4B). 
When compared with the ER+/ HER2- subgroups, the mean expression level of these 
estrogen signalling genes is the same at baseline in the ER+/HER2+ Responding subgroup as 
in both the ER+/HER2- Responding and Non Responding subgroup.  At this early stage, the 
ER+/ HER2+ Responders would appear to be more similar to the ER+/ HER2- tumours in 
terms of estrogenic signalling properties (Figure 4.4B). 
Figure 4.4B: Mean expression of estrogen signalling genes (ESR1; ESR2; PGR; GATA3; 
FOXA1; AGR2; NAT1; and BCL2) throughout 3 month treatment period with neoadjuvant 




This evidence suggests that even before treatment with neoadjuvant letrozole commences, the 
ER+/ HER2+ Non Responding subgroup is different in terms of estrogenic signalling 
pathways, and would support the hypothesis that this group of patients who do not respond to 





4.5 Differences in the Molecular Profiles Between ER+/ HER2+ Responders and Non 
Responders, at Baseline 
Differential gene expression analysis between the ER+/ HER2+ Responding and ER+/ 
HER2+ Non Responding subgroups at baseline, revealed distinct molecular profiles between 
the 2 subgroups (Figure 4.5).  
Analysis of the 230 most highly expressed genes in ER+/ HER2+ Non Responders, revealed 
pathways which were functionally enriched (DAVID Bioinformatics tool) in immune 
response pathways (67/230 genes; 29.3%) and in pathways involved in extracellular matrix 
remodelling (ECM) and focal adhesion (FA) (36/230 genes; 15.5%) (Figure 4.5). 
The 230 most highly expressed genes at baseline in the ER+/ HER2+ Responders subgroup 
include genes involved in molecularly distinct pathways (using DAVID Bioinformatics tool), 
from the ER+/HER2+ Non Responding group. These functional pathways include 
transcription and translation (40/230 genes; 17.4%); cell signalling (16 genes; 7%); metal 






4.6 Most Consistently Changed Genes in Responders  
Analysis of the 551 most consistently changed genes in ER+/ HER2– responders to letrozole 
therapy (pairwise RP, FDR=0.01) revealed pathways that were functionally enriched (DAVID 
Bioinformatics tool) in terms of both down-regulated and up-regulated genes at both the 14 
day and 3 month time-points.  
The most down regulated genes between pre-treatment and 14 days of letrozole were genes 
involved in the following pathways: proliferation/ cell cycle/ DNA replication; transcription; 
protein processing.  
The most up-regulated genes in this group over the same treatment period were involved in 
the immune/ inflammatory response and ECM/ stromal remodelling /adhesion and 




Figure:4.6A: Pie charts showing the functional groups which were most down regulated 





Proliferation associated genes including cyclins (CCNA2, CCNB1 and CCND1), the mini 
chromosome maintenance genes (MCM2, MCM4 and MCM6) and the mitotic spindle 
associated genes (ASPM and AURKA) were found to be down-regulated in both ER+/ 
HER2+ and ER+/ HER2- responding tumours by 14 days. Glycolysis and oxidative 
phosphorylation genes were found to be consistently down-regulated by 3 months in 
responding tumours (both ER+/ HER2- and ER+/ HER2+). 
Genes involved with the Immune/ inflammatory response and ECM/ stromal remodelling 
were found to be significantly up-regulated by 3 months in the responding tumours (both 
ER+/ HER2+ and ER+/ HER2- subgroups) (Figure 4.6B).  The same genes remained at a 
relatively low expression level at both on-treatment time points (14 days and 3 months) in 










4.7 Proliferation, Immune, Stromal, and ECM Remodelling Pathways 
A heatmap of the proliferation and immune/ stromal/ ECM genes effectively demonstrates the 
different patterns of gene expression change between the different ER+/HER2- and 
ER+/HER2+ Responders and Non Responders between pre-treatment and 3 months of 
neoadjuvant letrozole.(Figure 4.7A). The ER+/ HER2- Responding tumours and the ER+/ 
HER2+ Responding tumours had identical changes in these key genes, indicating that some 
ER+/ HER2+ tumours behave biologically like ER+/ HER2- tumours. It may be that in these 
responding ER+/ HER2+ tumours, HER2 signalling is inactive. 
The ER+/ HER2- Non Responders showed a similar down-regulation of proliferation genes 
but only minimal up-regulation of the immune/stromal/ECM genes. 
The heatmap demonstrates two different groups of ER+/HER2+ Non Responders. In the first 
group (pink) there was some down-regulation of proliferation genes over the 3 months of 
treatment with minimal up-regulation of the immune/stromal/ECM genes. This group would 
appear to behave in a similar way to the ER+/HER2- Non Responders.   
The remaining ER+/HER2+ Non Responders (purple) did not show any change in 
proliferation or immune/stromal/ ECM genes. In terms of change in gene expression, 










Multidimensional scaling (figure 4.7B) was used to plot the relationship of gene expression 
changes between pre-treatment and 3 months of letrozole therapy for each tumour. To 
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demonstrate the direction and extent of change in gene expression in each tumour, a line 
connecting baseline to 3 months was used to plot the trajectory of movement. An arrow 
starting in the blue ellipse on the left and moving to the green ellipse on the right represents 
the down-regulation of proliferation genes and up-regulation of immune/ stromal/ ECM 
remodelling genes as described above. 
 
Figure 4.7B : Multidimensional scaling (MDS) plot: Trajectory of changed genes from baseline 
samples (circles) and 3 month on-treatment samples (arrow heads). Left plot demonstrates 
trajectory of movement of all tumours (green: ER+/HER2- R; yellow: ER+/HER+ R; red: 
ER+HER2- NR; pink/purple: ER+/HER2+ NR). Right plot show all Non Responding tumours.  
 
Responding tumours moved from left to right (from the large light blue ellipse to the smaller 
green ellipse). This represents increased expression of immune/ ECM remodelling genes, and 
a decreased expression of proliferation genes.  Both ER+/ HER2- Responders (green arrows) 
and the ER+/ HER2+ Responders (yellow arrows) responding tumours had similar path 
trajectories, reflecting a similar change in gene profiles over the 3 months of treatment.   
Non responding tumours (MDS plot on the right) demonstrated less overall change in gene 
expression than responding tumours, with most not reaching the green ellipse.  The majority 
of ER+/ HER2- Non Responding tumours (red arrows) appeared to change in the same 
direction as the responding tumours but not to the same extent.  The ER+/ HER2+ Non 
Responding tumours either didn’t move at all (pink arrows) or showed an erratic pattern of 
movement (purple).   
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4.8 Immune cell profiling for ER+/ HER2+ tumours at baseline 
We have demonstrated that response to letrozole involves an increase in the expression of 
immune related genes (Figure 4.6A; Figure 4.6B; Figure 4.7A; Figure 4.7B). Gene 
expression signatures for individual immune cell types308 including All T cells; CD8+ T cells; 
T regulatory cells; B cells; and dendritic cells were used to create gene expression heatmaps 





Figure 4.8A: Heatmap of All T cells gene signature (gene list Appendix 4). Red: ER+/ 
HER2+ Non Responders; Orange: ER+/ HER2+ Progressors; Green: ER+/ HER2+ 
Responders. 
Figure 4.8B: Heatmap of CD8+ T cells gene signature (gene list Appendix 4). Red: 







Figure 4.8C: Heatmap of T regulatory cells gene signature (gene list Appendix 4). 








Figure 4.8D: Heatmap of B cells gene signature (gene list Appendix 4). Red: ER+/ 








Using the ‘All T cells’ gene signature there did appear to be clustering of the ER+/ HER2+ 
responders from the non responders (Figure 4.8A). This separation was not quite so evident 
when the other immune gene signatures were applied to heatmaps. 
 
Figure 4.8E: Heatmap of Dendritic cells gene signature (gene list Appendix 4). Red: 




4.9 ER Positive/ HER2 Positive Responders behave like ER Positive/HER2 Negative 
Responders 
We have demonstrated that response to letrozole involves a decrease in proliferation genes 
and an increase in immune, stromal and ECM remodelling genes. Just under half of the 
ER+/HER2+ tumours studied (8/17; 47%) did have a good response to letrozole therapy. 
Analysis of gene expression changes in these tumours shows a very similar profile to the 
ER+/HER2- Responders. (Figure 4.7A and Figure 4.8). This would suggest that HER2 
signalling is not present in these HER2+ tumours and that endocrine therapy is effective in 
these patients.  
 
Figure 4.9: Multidimensional scaling (MDS) plot: Trajectory of changed genes from baseline 
samples (circles) and 3 month on-treatment samples (arrow heads). Left plot demonstrates 
trajectory of movement of all responding tumours (green: ER+/HER2- R; yellow: ER+/HER+ 
R). Right plot shows all ER+/ HER2+ responding tumours.
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4.10 ER Positive/ HER2 Positive Tumours and Neoadjuvant Letrozole 
To further investigate the role of HER2 in endocrine resistance, analyses were focussed on 
the ER+/ HER2+ tumours and the ER+/ HER2- non responding tumours . 
To further assess the way in which the ER+/ HER2+ tumours responded to letrozole therapy, 
response was further broken down into tumours which were consistently ‘non responders’ 
(red); tumours which showed ‘partial response then progression’ (orange); and tumours which 
were ‘quick stable responders’ (green).  ER+/ HER2 negative non responding tumours (blue) 
were investigated to determine whether the pathways of resistance were different between the 
ER+/ HER2+ and ER+/ HER2- non responding tumours. (Figure 4.10) 
 
Figure 4.10: Clinical response groups. Change in tumour volume allows classification of 
response, red: ER+ /HER2+ Non Responders (NR); orange: ER+/ HER2+ Progressors (P) 
(partial response and then progression); green: ER+/ HER2+ Responders (R); blue: ER+/ 











4.11 Effect of endocrine therapy on proliferation, in ER+/ HER2+ tumours 
Using a published list of proliferation genes whose expression has been shown to decrease 
with endocrine therapy309 (Appedndix 4), it can be seen that following 3 months of 
neoadjuvant letrozole, expression of these proliferation genes remains higher in the ER+/ 
HER2+ non responding tumours.   
It can be seen that the ER+/ HER2+ Responders fall to the right of the heatmap, where there 
is a low level of expression of proliferation genes. The ER+/ HER2+ Non Responders fall to 
the left of the heatmap and can be seen to have high levels of expression of proliferation 
genes, indicative of letrozole resistance after 3 months of neoadjuvant therapy. 
 
Figure 4.11: Heatmap showing proliferation gene expression in all ER+/ HER2+ 




4.12 Active HER2 signalling via the MAPK signalling pathway, and estrogen signalling,   
pre-treatment  
Using published data of genes found to be involved in MAPK signalling289 (Appendix 5), and 
ER signalling310 (Appendix 6), it can be seen at the pre-treatment timepoint that ER+/ HER2+ 
tumours which will be resistant to letrozole are characterized by active MAPK signalling and 




The heatmap (Figure 4.12) demonstrates clustering of the tumours at baseline into active 
(left) and inactive MAPK signalling. It can be seen that the large majority of clinical 
responders demonstrate inactive MAPK signalling at the pre-treatment biopsy. This is also 
associated with a higher level of expression of ER signalling genes.   
The vast majority of non responding tumours (8/9) show active signalling at the pre-treatment 
level. Furthermore, this is associated with a lower level of expression of ER signalling genes. 
 
Figure 4.12: Heatmap showing expression of up regulated and down regulated 
genes indicating active or inactive MAPK signalling, and ER signalling for all 
ER+/ HER2+ samples at baseline. Expression levels of ESR1, ERBB2, PAX2 





The pre-treatment gene expression level of ESR1 and ERBB2 for each of the ER+/ HER2+ 
tumours can also be seen (Figure 4.12). A lower expression of ESR1 can be seen to the left of 
the heatmap where the majority of the non responders are, whereas a higher level can be seen 
to the right of the heatmap in the responding tumours. A higher expression of ERBB2 is seen 
in the non responding tumours to the left of the heatmap, compared to a lower level of 
expression in the responders to the right. 
The heatmap also demonstrates pre-treatment expression levels of PAX2 and the ER 
coactivator AIB1, genes which have been shown to compete for binding and regulation of 
ERBB2 transcription.353 There is a higher level of expression of PAX2 in the  responding 
tumours which is consistent with previous data that showed PAX2 to be associated with better 
sensitivity to endocrine therapy (Figure 4.12). There was no significant difference in 










4.13 Active HER2 signalling via the MAPK signalling pathway, and estrogen 
signalling, after 3 months neoadjuvant letrozole  
After 3 months of neoadjuvant letrozole therapy there is considerable change in the MAPK 
signalling activity. At this time point the tumour samples do not cluster into distinct 
responding and non responding arms (Figure 4.13). 
 
 
It can be seen that ER signalling remains lower in the ER+/ HER2+ non responding tumours 
after 3 months neoadjuvant letrozole. At this time point ER signalling is still active in the 
ER+/ HER2+ responders. This pattern of ER signalling activity after neoadjuvant letrozole is 
consistent with findings at pre-treatment biopsy in the responding and non responding groups 
(Figure 4.12).  
Figure 4.13: Heatmap showing expression of up regulated and down 
regulated genes indicating active or inactive MAPK signalling, and ER 




4.14 Immunohistochemistry, ERK and phosphorylated ERK 
Monoclonal antibodies for ERK and phosphorylated ERK (pERK) were used to stain 
formalin fixed, paraffin embedded slides. Staining of ERK and pERK was consistent with 
gene expression levels, however tissue was only available from a small cohort of the samples, 


















Figure 4.14A: Representative examples of paraffin embedded breast carcinoma tissue 
biopsies. Biopsies taken at pre-treatment (-1) and after 3 months treatment with 
neoadjuvant letrozole (-3). Samples analyzed by immunohistochemistry for ERK. Slides 


























Figure 4.14B: Representative examples of formalin fixed, paraffin embedded breast 
carcinoma tissue sections. Biopsies taken at pre-treatment (-1) and after 3 months 
treatment with neoadjuvant letrozole (-3). Samples analyzed by immunohistochemistry for 
phosphorylated ERK. Slides categorised into high, intermediate , low and negative 




4.15 Active HER2 signalling via the PI3K signalling pathway, pre-treatment 
The phosphatidylinositol 3' -kinase(PI3K)-Akt signalling pathway is activated by many types 
of cellular stimuli or toxic insults and regulates fundamental cellular functions such as 
transcription, translation, proliferation, growth, and survival. The binding of growth factors to 
their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class 
Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-
3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger 
that helps to activate Akt. Once active, Akt can control key cellular processes by 
phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell 
cycle. Using genes from the Kegg database PI3K signalling pathway (Appendix 7), heatmaps 











At the pre-treatment timepoint, the responders and non responders cluster seperately. It would 
appear that there is a distinct group of genes (cluster 2 on heatmap, Figure 4.15) which when 
Figure 4.15A: Heatmap showing expression of genes involved in PI3K 
signalling and an inverse correlation in expression of FOXO target genes, for 




highly expressed indicate inactive PI3K signalling and when expressed at low levels would 
indicate active PI3K signalling. Cluster 2 represents the genes AKT3, NFKBIA, SHC1, 
PIK3R1, SRF, GJA1, PDGFRA, FOS, PTEN, JUN, PDPK1, FOXO1, IGF1 and CDKN1B. 
Using this cluster of genes to represent activity of PI3K signalling, it can be seen that at 
baseline ER+/ HER+ Responders have no evidence of active PI3K signalling. The ER+/ 
HER+ Non Responders have evidence of active PI3K signalling, indicating that this 
signalling pathway could play an important role in resistance to endocrine therapy in these 
ER+/ HER2+ tumours. 
PI3K pathway activity negatively regulates forkhead box-O (FOXO) transcription factor 
activity, and so FOXO gene expression is inversely correlated with PI3K activity. Expression 
of FOXO target genes311 (Appendix 8) showed an inverse correlation with PI3K expression. 
ER+/ HER2+ responding tumours had high expression of FOXO target genes at baseline, 
whilst ER+/ HER2+ non responding tumours demonstrated a low level of expression of 


























 Figure 4.15B: The phosphatidylinositol 3' -kinase(PI3K)-Akt signalling pathway is activated 
by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions 





4.16  Active HER2 signalling via the PI3K signalling pathway, after 3 neoadjuvant 
letrozole 
In non responding ER+/ HER2+ tumours, PI3K pathway activity remains high, once again 


















Figure 4.16: Heatmap showing expression of genes involved in PI3K 
signalling and the inverse correlation in expression of FOXO target genes for 
each ER+/ HER2+ tumour after 3 months neoadjuvant letrozole therapy. 	
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4.17 Validation with treatment naive ER+/ HER2+ cohort 
To validate our findings we identified a further 13 patients with ER+/ HER2+ disease who 
had primary surgical excision of their tumour, without neoadjuvant letrozole. These patients 
were not part of the neoadjuvant letrozole study and as such do not have clinical response 
paramaters as measured by change in tumour volume. Follow up clinical data for recurrence 
is not yet available for these patients. Microarrays were generated for these 13 ER+/ HER2+ 



















Figure 4.17: Heatmap of treatment naïve cohort, 13 ER+/ HER2+ tumour 
samples. MAPK activity genes, ER signalling, ESR1, ERBB2, PI3K 




The left side of the heatmap (Figure 4.17) shows a group of ER+/ HER2+ tumours 
characterized by active MAPK and PI3K signalling suggesting active HER2 signalling. There 
is a lower level of ER signalling as well as a lower expression of ESR1 and a higher level of 
ERBB2 expression. Whilst there is no clinical data available yet for these patients, the 
findings would suggest that this group of patients would be more likely to develop resistance 
to adjuvant endocrine therapy. 
The right side of the heatmap (Figure 4.17) demonstrates a group of tumours that would be 
more likely to have a sustained response to adjuvant endocrine therapy. These tumours 
samples have inactive MAPK and PI3K signalling pathways, a higher ER signalling activity 














4.18 Signalling pathways in ER+/ HER2 Negative tumours, Non Responders 
 
Microarray data was available for 11 ER+/ HER2- non responding tumours in patients who 
received 3 months of neoadjuvant letrozole. These tumour samples were investigated for 
proliferation gene activity (Figure 4.18A), MAPK gene activity (Figure 4.18B), and PI3K 
signalling activity (Figure 4.18C).  
 




When the same set of proliferation genes (Appendix 4) was applied to the ER+/ HER2- non 
responders (Figure 4.18A), most of these tumours had a low expression of proliferation genes 
at baseline and after 3 months neoadjuvant letrozole therapy.  
Figure 4.18A: Heatmap representing the same proliferation genes to ER+/ HER2+ NR 















When the same set of MAPK activity genes (Appendix 6) was applied to ER+/ HER2- Non 
Responders at baseline and at 3 months there was a mixed picture with 4/9 of the ER+/ 
HER2- NR tumours showing evidence of active MAPK signalling at baseline (Figure 4.18B). 
2 of these tumours (samples 76 and 121) continued to show active MAPK signalling after 3 
Figure 4.18B: Heatmap showing expression of up regulated and down regulated genes 
indicating active or inactive MAPK signalling, for all ER+/ HER2+ samples (NR, P, R) and 
ER+/ HER2- NR at pre-treatment and 3 month intervals. Colour bar at left indicates 




months treatment, whilst 2 tumours which had inactive signalling at baseline developed 
evidence of MAPK signalling at 3 months (samples 81 and 331). Whilst there is 
demonstration of active MAPK signalling in the ER+/ HER2- non responding tumour at both 
the pre-treatment and 3 month timepoints, the clustering is much less consistent than that seen 
with ER+/ HER2+ Responding and Non Responding tumours.  
 












Using the same PI3K signalling genes (Appendix 7) it can be seen at the pre-treatment level 
that many of the ER+/ HER2- Non Responders do not show evidence of active PI3K 
signalling. After 3 months neoadjuvant letrozole, the majority of ER+/ HER2- NR do show 
evidence of active PI3K signalling.  
Whilst there are similar changes in these PI3K signalling genes in both the HER2 positive and 
HER2 negative Non Responding groups after 3 months neoadjuvant letrozole, at the pre-





Figure 4.18C: Heatmap of ‘Cluster2’ genes at pre-treatment and 3 month timepoints for 
ER+/ HER2+ NR (red), P (orange), R (green) and ER+/ HER2- NR (blue). 
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the majority of the HER2+ at this pre-treatment level do already show evidence of PI3K 
signalling. This suggests that there is a difference in PI3K signalling between the ER+/ 
HER2+ and the ER2+/ HER2- subgroups, which could be determined before treatment with 
endocrine therapy begins.  
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4.19 UK wide survey of HER2 testing and HER2 targeted therapies 
As part of the work for this thesis a survey of UK surgeons was performed. The survey found 
that some UK centres do not test for HER2 on initial diagnostic core biopsies. The resulting 
delay in HER2 positive diagnosis potentially denies patients access to neoadjuvant anti-HER2 
therapy. UK surgeons reported that in most units less than 75% of all HER2 results were 
available for the multidisciplinary meeting after surgery when decisions were made on 
adjuvant treatment. This figure is remarkably similar to results from a UK audit in 2008. 
Draft quality assurance guidelines have set a figure of 85% of HER2 test results being 
available for the preoperative multidisciplinary meeting, but few units currently meet this 
target. If we fail to achieve this target for HER2 testing it makes if impossible to deliver on 
the wider range of prognostic and predictive factors that are now in development. 
Given the importance of HER2 as a prognostic and treatment related factor, almost all 
invasive cancers are now tested for the presence of HER2 over-expression. Treatments 
directed against HER2 have substantially improved the outcome for HER2 positive patients 
with breast cancer.  With this in mind, as part of this study a survey of breast surgeons across 
the United Kingdom was conducted to ascertain how many breast cancer units were testing 
their patients for HER2, and how efficient this testing was. 
Survey responses were returned from 187 centres across the UK. The survey revealed that 
only half of patients with invasive cancer had a HER2 result available when treatment was 
initially discussed. The survey found that some UK centres (12%) did not test for HER2 on 
initial diagnostic core biopsies. Overall, less than 75% of HER2 results were available for the 
multidisciplinary team (MDT) meeting, when decisions were made on adjuvant treatment. 
Draft quality assurance guidelines have set a figure of 85% of HER2 test results being 
available for the preoperative MDT. Few units currently meet this target. Full results of the 
survey are shown in Figure 4.4 and the questionnaire that was sent to surgeons can be seen in 




Figure 4.19: Results from 187 UK breast cancer surgeons following a survey on current 




5. Discussion                                                                                                                                                                               
The ER positive/ HER2 positive subtype accounts for up to 10% of all breast cancers and is 
an important subtype as these cancers have a worse prognosis than ER+/ HER2 negative 
breast cancers. This study uses the largest dataset of ER+/ HER2+ matched breast cancer 
samples before and during therapy to assess the effects of neoadjuvant letrozole on tumours. 
Whist there is now considerable preclinical and clinical evidence that ER+/ HER2+ tumours 
exhibit intrinsic and acquired resistance to endocrine therapy, it remains unclear what is 
driving this resistance to therapy.  Clearly this is a pressing clinical issue as endocrine therapy 
remains at the forefront of systemic treatment for all women with ER positive disease.  
However, many patients with ER+/ HER2+ disease do respond well to endocrine therapy.  
The challenge therefore, is in identifying, early in the process of treatment decision making, 
who will respond to endocrine therapy, and who might benefit from combined endocrine and 
HER2 targeted agents.    
Over recent years a variety of targeted therapies have evolved which inhibit specific targets 
and pathways that play key roles in tumour growth and progression. Despite these new 
developments, endocrine therapies that block ER activity and signalling, remain at the 
forefront of systemic treatment in women with ER positive disease.  Optimal systemic 
management of breast cancer requires consideration of clinical, pathological and biological 
parameters.  The development of high throughput global gene expression profiling has come 
into use as a way of defining, at the molecular level, the phenotypes of many kinds of 
tumours.  In 2000 Perou et al described the molecular heterogeneity of breast cancer, as 
determined by microarray gene expression profiling and defined the ‘intrinsic‘ molecular 
subtypes of breast cancer, namely luminal A (ER+/ HER2-/ low proliferation), luminal B 
(ER+/ HER2-/ high proliferation), HER2-like and basal-like (ER-/ HER2-).78  These subsets 
were defined mostly by known prognostic parameters (estrogen receptor, HER2 and 
proliferation) and they exhibit differences in prognosis and treatment sensitivity. There are 
now several commercially available gene expression assays which are designed to aid the 
clinician to objectively estimate patient outcome, and to estimate the benefits from systemic 
adjuvant endocrine therapy and chemotherapy.  The available molecular assays have not yet 
conclusively identified a good prognostic subset of HER2 positive breast cancers that require 
less aggressive systemic therapy. 
Whilst the ER negative/ HER2+ subtype of breast cancers is a relatively well characterised 
group in terms of tumour biology and behaviour, the ER+/ HER2 + subtype is less so.  HER2 
positive cancers account for 15-20% of all breast cancers and 50% of these are ER positive.  
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It has been unclear as to whether ER signalling or HER2 signalling drives resistance to 
endocrine therapy in the ER+/HER2+ subset.   
In postmenopausal women with large, locally advanced, estrogen receptor rich breast cancers, 
neoadjuvant endocrine therapy is an appealing option as many older women may not be able 
to tolerate the toxicities of chemotherapy.  In these women, neoadjuvant endocrine therapy 
can be used effectively to shrink tumours, rendering them amenable to breast conserving 
surgery, as opposed to mastectomy.  In tumours suitable for breast conserving surgery, 
neoadjuvant endocrine therapy can shrink the tumour so that a smaller surgical resection is 
required, allowing for improved cosmetic outcome.  Furthermore, patients with locally 
advanced breast cancer have a poorer prognosis than patients with early breast cancer, and 
whilst neoadjuvant treatment was initially dominated by chemotherapy, studies have shown 
response rates to neoadjuvant treatment with aromatase inhibitors in selected hormone 
receptor positive patients is comparable to that seen with neoadjuvant chemotherapy.177 
Women with locally advanced breast cancers may also benefit from endocrine therapy in 
terms of survival, and it allows women to avoid the more unpleasant toxicities associated with 
chemotherapy.  This is all the more important as hormone receptor positive tumours have 
repeatedly been shown to have lower response rates to neoadjuvant chemotherapy than 
hormone receptor negative tumours, in terms of pathological complete response.247,248,249 pCR 
rates of less than 15% have been reported with neoadjuvant anthracycline-taxane therapy in 
luminal-type breast cancer.238 
Whilst systemic treatment of HER2 positive disease has been dominated by chemotherapeutic 
agents, there is a need to explore whether the combination of HER2 targeted and endocrine 
therapy in this group of ER+/HER+ patients might firstly tackle the problem of endocrine 
resistance in these patients, and secondly, whether some of these patients might be treated 
safely and effectively with this combined therapy, and might avoid the need to use 
chemotherapy in these women. Given the clear importance of HER2 as a prognostic and 
treatment related factor, it was felt that as part of this study it would be useful to explore the 
current practices of HER2 testing conducted by breast surgeons across the UK. Indeed, it was 
a concerning finding that only half of patients with invasive cancer had HER2 test results 
available when their treatment plans were initially discussed. This would mean that in the 
other half of patients who did not have HER2 results available, neoadjuvant HER2 directed 
therapy could not even be considered. 
The neoadjuvant setting allows prompt testing and evaluation of therapies and provides 
reliable results to inform and direct the design of adjuvant trials.  The POETIC trial is a phase 
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III, multicentre trial for postmenopausal women with ER/ PR positive invasive breast cancer 
to determine whether 2 weeks perioperative aromatase inhibitor (AI) therapy before and after 
surgery improves outcome compared with standard adjuvant alone. It is the UK’s largest 
perioperative trial, with recruitement of 4,486 patients from 130 UK sites over a 5.5 year 
period. Whilst results showed no evidence of improved clinical outcome with perioperative 
aromatase inhibitor therapy, the study did provide evidence that measuring Ki67 levels at 
baseline and at 2 weeks of therapy offered significant and independent prognostic 
information. For patients with high baseline Ki67 values (10% or greater) at both baseline and 
after 2 weeks of perioperative AI therapy, the 5 year absolute risk for recurrence was 19.6% 
compared with 8.9% for those with high baseline but low 2-week Ki67 levels, and 4.5% for 
for those with low levels at both time points.    
It is clear that this neoadjuvant approach is becoming increasingly important in the 
investigation of endocrine resistance, and has been an effective way of looking at the ER+/ 
HER2+ group of breast cancers in this study.                   
The objectives of this study were 3 fold:                   
1. To investigate which ER+/ HER2+ breast cancers respond to letrozole. 
2. To compare the mechanisms of resistance to endocrine therapy in ER+/ HER2+ and 
ER+ / HER2- breast cancers. 
3. To determine which cancers should be considered for combined endocrine and anti-
HER2 treatment.  
While HER2 undeniably plays an important role in resistance to endocrine therapy, half of the 
ER+/ HER2+ patients in this dataset did respond well to neoadjuvant letrozole. There are now 
several commercially available gene-expression assays that are designed to aid the clinician to 
objectively estimate patient outcome and to estimate response to systemic therapy. The 
available molecular assays have not yet conclusively identified a good prognostic subset of 
HER2+ breast cancers that might require less aggressive systemic therapy.   
 
ER+/ HER2+ Responding tumours behave more like ER+/ HER2- tumours 
A group of ER+/ HER2+ endocrine sensitive cancers has been identified, which appear to 
have a less aggressive phenotype and behave biologically more like ER+/ HER2- tumours.  
These ER+/ HER2+ tumours had a clinical response to neoadjuvant letrozole, equal to that of 
the ER+/ HER2- endocrine sensitive tumours.  These tumours demonstrate their sensitivity to 
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neoadjuvant letrozole with an overall down regulation of expression of proliferation 
associated genes (Figure 4.11). Furthermore, the ER+/ HER2+ responding tumours did not 
demonstrate evidence of MAPK or PI3K signalling at the pre-treatment level.  
It is likely that in these ER+/ HER2+ endocrine sensitive tumours, estrogen rather than HER2 
is driving the growth of these tumours.  This finding complements results from 2 previous 
phase III adjuvant trials performed in the metastatic setting.  In the randomised Phase III TAn-
DEM trial of patients with ER+/ HER2+ metastatic breast cancer, there was a doubling of 
progression-free survival time with the addition of trastuzumab to anastrozole alone.297  
Johnston el al. also showed a significantly increased PFS for a combination of letrozole plus 
lapatinib compared with letrozole alone.298 Interestingly, in the aromatase inhibitor only arm 
in both of these trials approximately 20% of ER+/ HER2+ metastatic breast cancer patients 
had no progression at 1 year. These tumours may represent a good prognostic subset of 
HER2+ breast cancers that might require less aggressive systemic therapy. The challenge 
remains in accurately selecting the ER+/ HER2+ patients who are resistant to endocrine 
therapy and who are likely to benefit from combined endocrine and HER2 targeted therapy. 
 
Expression of ERBB2 in Responding and Non Responding tumours 
Despite all ER+/ HER2+ tumours being IHC 3+ or IHC 2+ FISH positive, the level of 
expression of the ERBB2 gene was significantly higher in the ER+/ HER2+ non responding 
group responding ER+/ HER2+ group (p=0.005, Figures 4.2 and 4.12).  
At the pretreatment level ERBB2 expression was the same in both the ER+/ HER2- 
responding and non responding groups. However, in the ER+/ HER2- non responding tumours 
there was an increased expression of ERBB2 during the 3 month neoadjuvant treatment period 
(Figure 4.3). This suggests that even in HER2- tumours HER2 signalling could play a role in 
endocrine therapy resistance. 
 
ER+/ HER2+ Non Responding tumours demonstrated less estrogen signalling activity 
than ER+/ HER2+ Responding tumours 
Whilst all tumours involved in this study were estrogen rich (Allred score ≥6), the expression 
level of the ESR1 gene was significantly lower in the ER+/ HER2+ non responding group than 
in the ER+/ HER2+ responding group (Figures 4.4A and 4.12) .  
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It has been suggested that conventional quantification of nuclear ER IHC staining is not 
sufficiently specific in detecting functional ER pathway activity. According to pathology 
guidelines, ER activity in a breast cancer tissue sample is inferred from the presence of 
positive ER staining, with a minimum of 1% of ER positive tumour nuclei as a threshold 
level. To quantify a measure of ER pathway activation, one group has created an ER pathway 
gene model.310 Functional activity of the ER signalling pathway was determined by mRNA 
expression data of ER transcriptional target genes, which were interpreted in a weighted 
manner, to calculate a probability of pathway activation. Using this ER pathway gene model it 
can be seen that the ER+/ HER2+ responding tumours exhibit higher ER signalling activity 
than the non responding tumours at the pre-treatment level (Figure 4.12).  
Studies have shown that expression of a transcription factor known as PAX2 is associated 
with better sensitivity to endocrine therapy due to its role in the ER mediated repression of 
HER2. One study has reported that the response of cells to tamoxifen is regulated by 
competition between the ER coactivator AIB1 and PAX2 binding to the cis-regulatory 
elements in intron 4 of HER2. They showed that a decrease in expression of PAX2 in 
tamoxifen resistant cells correlated with an increase in HER2 expression.353  Furthermore, 
IHC staining of tamoxifen treated, ER positive breast cancers showed that PAX2 expression 
in the abscence of AIB1 correlated with recurrence free survival and a low rate of HER2 
expresion.354  Expression of PAX2 and AIB1 was measured in ER+/ HER2+ responding and 
non responding tumours at baseline (Figure 4.12). It can be seen that there was a higher 
expression of PAX2 in responding tumours than non responding tumours, in keeping with 
previous findings that PAX2 is associated with better sensitivity to endocrine therapy. The 
level of expression of AIB1 was not different between the responding and non responding 
groups, a result which is difficult to intreprit in this small sample size. 
 
Immune response and immune cell signatures  
Previous studies in patients receiving neoadjuvant aromatase inhibitor treatment, have shown 
suppressed expression of genes associated with proliferation an estrogenic signalling, and an 
increased expression of genes involved with stomal remodelling, cell adhesion, and immune 
response.354,355,356 In this study, tumours that had a good clinical response to neoadjuvant 
letrozole, showed significant up regulation of genes involved in immune response (Figures 
4.6A & B). This was apparent in both ER+/ HER2+ responding tumours and ER+/ HER2- 
responding tumours, once again providing evidence that this group of endocrine sensitive 
ER+/ HER2+ tumours appear to behave more like ER+/ HER2- tumours.  
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The ER+/ HER2- tumours that were resistant to endocrine therapy did show similar changes 
in up regulation of stromal/ immune response genes and down regulation of proliferation 
genes, although not to the same extent and it is this that is likely to account for the endocrine 
resistance seen in these tumours. Indeed, it may be that with sustained endocrine therapy that 
these tumours would have shown improved clinical response.  
The clinical relevance of the immune system in cancer has been demonstrated by the growing 
field of immune therapies, where they have made a significant impact in the fields of lung 
cancer and melanoma.312,313 However, despite the positive response to immune therapy 
experienced by a subset of patients, the identification of biomarkers to determine which 
patients will benefit from these agents remains a challenge. Using immune cell gene 
expression signatures,308 pre-treatment ER+/ HER2+ samples were investigated to determine 
whether the responding tumours were more like a particular individual immune cell type than 
the ER+/ HER2+ non responding tumours. Interpretation of the results was mixed, but many 
of the ER+/ HER2+ responding tumours had a stronger ‘All T-cell gene signature’ at baseline 
Figure 4.8A). Analyses were also performed for CD8+ T-cells, T regulatory cells, B-cells, and 
Dendritic cell gene signatures there did not appear to be any consistent separation between the 
ER+/ HER2+ responding and non responding tumours.  
 
Estrogen response is associated with reduced proliferation 
Using a published proliferation gene set,309 non response to 3 months of neoadjuvant letrozole 
therapy in ER+/ HER2+ tumours was associated with an up regulation of proliferation genes, 
whilst there was a down regulation of proliferation genes in the ER+/ HER2+ responders 
(Figure 4.11). This group of ER+/ HER2+ endocrine resistant tumours is likely to be driven 
by active HER2 signalling and would benefit from the addition of an anti-HER2 targeted 
agent.  
Analysis of the ER+/ HER2- endocrine sensitive tumours showed a clear association between 
good response and up regulation of stromal and immune response genes, and down regulation 
of proliferation genes.  During the first 14 days of neoadjuvant letrozole there was a 
significant down regulation of genes known to be involved in the cell cycle (eg AURKA and 
ASPM, Figure 4.6A).  Interestingly, a very similar molecular response was observed in the 
ER+/ HER2+ responding tumours, with up-regulation of stromal and immune response genes 
and down regulation of proliferation genes. Thus providing more evidence that there is a less 
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aggressive group of ER+/ HER2+ tumours that behave biologically more like ER+/ HER2- 
tumours.  
 
HER2 and the Mitogen-Activated Protein Kinase (MAPK) and Phosphoinositide 3-
Kinase (PI3K) signalling pathways 
Overexpression of the HER2 receptor via amplification of the ERBB2 gene, results in ligand 
independent homo-dimerization and constitutive signalling primarily through the 
phosphoinositide 3-kinase (PI3K) cascade.314 315 Mutational activation of the PI3K pathway is 
known to mediate resistance to HER2 targeted therapies in both pre-clinical models and 
through retrospective analysis of clinical data.316 Consequently, many small molecules 
targeting components of the PI3K cascades, including PI3K, AKT, and mTOR inhibitors, are 
currently undergoing clinical trials in combination with HER2 therapy.317 
The mitogen activated protein kinase (MAPK) signalling cascade is another pathway hyper-
activated in a large number of cancers. Whilst the pathway is not known to play a critical role 
in HER2 amplified cancers, the dual inhibition of PI3K and MAPK cascades can result in 
synergistic effects on cell proliferation and apoptosis in multiple cancer models,318 including 
HER2 positive breast cancer.319, 320 This suggests a potential role of MAPK signalling in the 
growth and survival of HER2+ cancers.  
It was hypothesised that both the PI3K and MAPK signalling pathways can potentiate HER2 
activity and that together these signalling pathways can cause resistance to endocrine therapy 
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MAPK signalling and endocrine resistance 
The activation of mitogen-activated protein kinase (MAPK, originally called ERK, 
extracellular signal-regulated kinase) in breast cancer is associated with ER negative breast 
cancer, and it is proposed that this MAPK up regulation is associated with estrogen 
withdrawal.321 Creighton et al hypothesized that aberrant growth factor signalling resulting in 
hyperactivation of MAPK would induce a gene expression profile reflective of the 
hyperactive MAPK and that this would affect breast cancer behaviour.289 In their study, they 
attempted to define a ‘hyperactive MAPK signature’ set of genes whose expression is altered 
in breast cancer cell lines as well as tumours with high MAPK activity. Using ERα MCF-7 
cells engineered for over expression of different growth factor signalling pathways, they 
developed models to mimic the MAPK hyperactivation seen in ERα negative breast cancers. 
They then examined gene expression patterns of ERα positive tumour profiles and found a 
subset of ERα positive, MAPK positive tumour profiles which had significant similarities to 
the ERBB2 specific mRNA signature. 
Figure 5.1: HER2 activity depends on 2 oncogenic signalling pathways, PI3K and 
MAPK and together these signalling pathways cause endocrine resistance in ER+/ 
HER2+ breast cancers. 
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When this 44 gene signature was applied to the ER+/ HER2+ breast cancers, it could be seen 
at the pre-treatment level that the majority of ER+/ HER2+ responding tumours did not have 
evidence of MAPK signalling. At the pre-treatment level, the majority (8/9 ER+/ HER2+ NR 
samples) of the ER+/ HER2+ non responding tumour samples did show evidence of active 
MAPK signalling (Figure 4.12). This findings support the hypothesis that active MAPK 
signalling plays an important role in endocrine resistance in ER+/ HER2+ breast cancer. This 
finding is clinically important as these ER+/ HER2+ cancers will derive no benefit from 
letrozole and would benefit instead from a HER2 and/ or a MAPK targeted agent.   
 
PI3K Signalling and endocrine resistance 
The phosphatidylinositol 3-kinase (PI3K) pathway is on of the main cellular growth factor 
signalling pathways, frequently hyperactivated in cancer.322 This signalling pathway has been 
associated with resistance to endocrine therapy, HER2 directed therapy and cytotoxic therapy 
in breast cancer.323, 324, 325 The PI3K/AKT/mTOR pathway is an intracellular signalling 
pathway which is important in regulating the cell cycle. In many cancers, this pathway is 
overactive, causing reduced apoptosis and allowing proliferation. 
It is reported that the PIK3CA gene is the second most frequently mutated oncogene, and 
PTEN is among the most frequently mutated tumour suppressor genes in cancers.330,331  The 
significant role of PI3K activation in tumour cell biology has led to several efforts to target 
PI3K and/ or downstream kinases such as AKT and mammaian target of rapamycin (mTOR) 
in cancer. However, clinical data shows limited single-agent activity of inhibitors targeting 
PI3K, AKT or mTOR. 
Using genes from the KEGG (Kyoto Encyclopedia of Genes and Genomes) database PI3K-
AKT signalling pathway, gene expression levels for ER+/ HER2+ responding and non 
responding tumours at baseline and after months neoadjuvant letrozole were displayed on 
heatmaps (Figure 4.15 and Figure 4.16). There was a distinct cluster of 14 genes (AKT3, 
NFKBIA, SHC1, PIK3R1, SRF, GJA1, PDGFRA, FOS, PTEN, JUN, PDPK1, FOXO1, IGF1 
and CDKN1B) which at a low expression level would indicate active PI3K signalling.  
The mechanism behind this activity is thought to be 2-fold. Firstly, there is down-regulation of 
CDKN1B which encodes for p27Kip1, a protein which belongs to the Cip/Kip family of cylcin-
dependent kinase (Cdk) inhibitor proteins, which is a potent inhibitor of cyclin-dependent 
kinases. p27Kip1 binds to and prevents the activation of cyclin-CDK complex’s, and thus 
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controls the cell cycle progression at G1. p27Kip1 is often referred to as a cell cycle inhibitor 




The second mechanism behind activation of PI3K signalling seen in ER+/ HER2+ non 
responding tumours is the low expression of PTEN. PTEN is a natural inhibitor of the 
PI3K/AKT pathway, it regulates PI3K signalling by dephosphorylating the lipid signalling 
intermediate PIP3. This dephosphorylation is important because it results in inhibition of the 
AKT signalling pathway. PTEN is one of the most commonly lost tumour suppressors in the 
cancer pathway and its inactivation is thought to be responsible for a variety of human 
cancers.326,327,328  A network involving the mutual dependence of PTEN and p53 has been 
suggested. Specifically, PTEN may protect p53 from Mdm2-mediated degradation, whereas 
p53 can enhance the transcription of PTEN.329 
At both the pre-treatment and 3 month treatment timepoints the ER+/ HER2+ responding and 
ER+/ HER2+ non responding tumours clustered separately, indicating inactive and active 
PI3K signalling respectively.  
Figure 5.2: In order to enter S phase, cells must activate CDK4/6 and CDK2. These 
kinases are expressed throuout the cell cycle, but are only activated upon complex 
formation with their corresponding cyclins. During early G1 phase, mitogenic signals 
trigger activation of the CDK4/6-cyclin D complex, which partially deactivates Rb by 
phosphorylation.  Cyclin A facilitates progression through S and G2 phase. Upstream 
inhibitors, including members of the Kip families, inhibit the mitogenic action of CDKs. 
Small molecule CDK4/6 inhibitors act primarily by blocking Rb phosphorylation and 
thus inducing G1 cell cycle arrest. 
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Current clinical data suggests that despite selection of potentially responsive patients based on 
PI3K pathway mutation analysis, only a subpopulation of patients respond adequately to PI3K 
pathway inhibitors.332,334  To improve prediction of response to PI3K inhibitor therapy, a test 
that can reliably measure functional PI3K pathway activity in cancer samples would be 
valuable. Forhead box-O (FOXO) transcription transcription factors are negatively regulated 
by the PI3K pathway and can in principle be used as an inverse correlation for PI3K pathway 
activity.311,336,337 A FOXO activity model has been developed as a method for quantitative 
assessment of functional PI3K pathway acitivity in tissue samples, and to improve prediction 
of response to drugs that target the receptor tyrosine kinase/ PI3K/ AKT pathway.311 This 
model of FOXO gene acitiviy was used to determine further evidence of PI3K activity in the 
letrozole resistant ER+/ HER2+  tumour samples.  At both the pre-treatment and 3 month 
timepoints there was reduced expression (and inverse correlation with PI3K activity) in ER+/ 
HER2+ Non Responding tumours (Figure 4.15 and Figure 4.16).  
The PI3K signalling pathway is active at both the pre-treatment and 3 month timepoints, 
providing evidence that this pathway plays an important role in endocrine resistance in ER+/ 
HER2+ breast cancers. 
 
 
Letrozole resistance in ER+/ HER2 negative tumours 
 
11 patients with ER+/ HER2- tumours were resistant to neoadjuvant letrozole. Unlike the 
ER+/ HER2+ non responding group, these tumours did not show a higher level of expression 
of proliferation genes at baseline, and did not have an increased expression of these genes 
throughout the 3 month treatment time period. There was some MAPK activity demonstrated 
in these tumours at both the pre-treatment and 3 month timepoints, this activity was much less 
evident than that seen in the ER+/ HER2+ non responding tumours. Whilst there was no PI3K 
signalling seen in the ER+/ HER2- non responding tumours at the pre-treatment level, most of 
these tumours did demonstrate active PI3K signalling after 3 months neoadjuvant endocrine 
therapy.    
 
Combating Endocrine Resistance 
Estrogen responsiveness may be lost by upregulating proliferation/ survival signal 
transduction pathways, like upstream signalling transmembrane growth factor receptors such 
as HER2 and downstream intracellular signalling such as the MAPK or PI3K/ AKT/ mTOR 
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signalling pathways. In patients with ER+/ HER2+ breast cancers, modulation of these 
pathways in combination with endocrine therapy, may circumvent resistance mechanisms.  
Multiple inhibitors of the PI3K/Akt/mTOR pathway are in preclinical development or are 
already in clinical trials. The mTOR inhibitor everolimus and EGFR inhibitor gefitinib can 
reverse the PI3/ AKT/ mTOR mediated resistance to endocrine therapy with used in 
combination with endocrine therapy.337 Everolimus is now in wide use in combination with 
exemestane (a steroidal aromatase inihibitor) after being shown to improve PFS in second or 
third line treatment of patients with ER positive metastatic breast cancer.339 Benefit has also 
been reported from the addition of fulvestrant (a selective estrogen receptor degrador) to 
everolimus in tamoxifen resistant breast cancer.340  
In preclinical studies, the mTOR inhibitor Temsirolimus inhibited proliferation of breast 
cancer cell lines that were estrogen dependent and overexpressed the HER2 receptor, 
suggesting that temsirolimus might be a useful treatment for ER+/ HER2+ breast cancers.341 
In a randomised phase II study of postmenopausal women with locally advanced or metastatic 
ER positive breast cancer, who had been heavily ‘pretreated’, addition of temsirolimus to 
letrozole showed antitumour activity and a generally tolerable safety profile.342    
Neratanib is an irreversible small-molecule tyrosine kinase inhibitor of HER1, HER2, and 
HER4. The US FDA approved 1 year of extended adjuvant neratinib after chemotherapy and 
a year of trastuzumab for HER2 positive breast cancer based on the results of the ExteNET 
trial.343 In the 5 year follow up analysis, it can be seen that most benefit was found in the 
hormone receptor (HR) positive population. Patients with HR positive disease were treated 
with concurrent endocrine therapy (either tamoxifen or an aromatase inhibitor) and it has 
been speculated that neratinib works in part by a mechanism other than HER2 inhibition. As 
well as inhibition of the HER receptors, it is also known to inhibit the MAPK pathway. 344 It 
may be that this agent can block ‘cross-talk’ down-stream signalling and stimulation of 
growth via the estrogen receptor, and indeed may only work with concurrent endocrine 
therapy. Of note is that neratinib is not currently approved for use in breast cancer treatment 
in the UK. 
 
The cyclin dependent kinases (CDKs) play an important role in regulating cell cycle 
progression. CDK4 and CDK6, activated by cyclin D, facilitate the hyperphosphorylation of 
retinoblastoma protein (pRb), which can lead to the cell cycle transition from G1 phase to S 
phase. This critical Rb checkpoint has been demonstrated to be associated with endocrine 
resistance in breast cancer. Recently, several high-quality clinical randomized controlled trials 
have identified that CDK 4/6 inhibitors have a great safety and efficacy, and can be used in 
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combination with letrozole or fulvestrant for women with advanced breast cancer which has 
progressed while receiving endocrine therapy.345 The PALOMA-1346 and PALOMA-2347 trials 
were designed to assess the safety and efficacy of the combination of palbociclib and 
letrozole as a first-line therapy for postmenopausal women with ER positive/ HER2 negative, 
advanced breast cancer. The results showed that patients in the pablbociclib-letrozole group 
had a longer median PFS (>10months) than those in the letrozole only group. PALOMA-3 
studied the combination of palbociclib and fulvesterant as a second line treatment for women 
with ER positive/ HER2 negative metastatic breast cancer and progression after prior 
endocrine therapy. Adding palbociclib to fulvestrant led to a significant improvement in 
median PFS from 3.8 months to 9.2 months. In addition to plabociclib, 2 other highly 
selective CDK4/6 inhibitors, ribociclib and abeciclib, are currently been in clinical 
development. Ribociclib has been tested as a first line therapy in the MONALEESA-2 trial, 
which reported that addition of this therapy to letrozole also prolonged duration of PFS.348 
The MONARCH-1 and -2 trials studied abeciclib, in MONARCH-1 this agent was given as 
monotherapy to women who had disease progression after endocrine therapy and 
chemotherapy, and in MONARCH-2 it was given in addition to fulvestrant. Results have 
shown significantly improved PFS (of 16.4 months) and overall response rate with abeciclib 
plus fulvestrant versus placebo versus fulvestrant.349,350 Related preclinical studies have 
shown that HER2+ breast cancer cell lines are sensitive to CDK4/6 inhibitors, indicating that 
HER2+ breast cancer patients may also benefit from treatment with CDK4/6 inhibitors.351 In 
contrast, one preclinical study of breast cancer cell lines, has shown there was no significant 
effect of CDK4/6 inhibitors on the triple negative subtype of breast cancer, suggesting that 
these agents play a role in HER2 signalling.352 Whilst more clinical data is needed, this 
suggests a role for dual targeting of the HER2 and CDK4/6 pathways.  
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6. Conclusions and Future Perspectives 
The results presented in this thesis suggest there are 2 distinct groups of ER+/ HER2+ cancers 
whose response to endocrine therapy depends on whether tumour growth is driven by estrogen 
or by HER2. This finding is clinically important as some ER+/ HER2+ cancers will derive no 
benefit from letrozole and would benefit instead from a HER2 and/ or a MAPK or PI3K 
targeted agent.   
Many of the ER+/ HER2+ tumours which had good clinical response to endocrine therapy 
showed down regulation of proliferation genes and inactive MAPK and PI3K signalling 
pathways.  
This study has shown that different signalling pathways are active and responsible for 
resistance to endocrine therapy in tumours that are ER+/ HER2+. Whilst it seems clear that 
HER2 plays an important role in resistance to endocrine therapy, many of the ER+/ HER2+ 
tumours were sensitive to endocrine therapy. This would suggest that HER2 positivity alone is 
not responsible for resistance to endocrine therapy and that this resistance relies in part on 
active MAPK signalling, active PI3K signalling and active HER2 signalling. 
Defining which ER+/HER2+ patients will not respond to endocrine therapy is an important 
clinical need, as it is likely that these patients will benefit from anti HER2 therapy.  
Furthermore, identifying a subset of ER+/HER2+ positive cancers which have a less 
aggressive phenotype could mean that these patients could be treated safely and effectively 
with combined endocrine and HER2 targeted therapies, without the need for chemotherapy.  
Data from available molecular assays have so far not definitively identified such a group. 
In this study of postmenopausal women with large or locally advanced ER rich/ HER2 
positive patients, who have been treated with 3 months of neoadjuvant letrozole, patients 
could be divided in to two clear response groups. Analysis of gene expression data showed 
different molecular profiles between these 2 groups at baseline, and differences in gene 
expression changes throughout treatment, both in terms of the functional molecular pathways 
that change over time and activation of MAPK and PI3K signalling pathways.  
Activation of both the MAPK and PI3K signalling pathways appears to be an important driver 
of endocrine resistance in some ER+/ HER2+ tumours. This may represent a subgroup of 
ER+/ HER2+ tumours that would benefit from MAPK and PI3K targeted therapies.  
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Whilst this study uses the largest dataset of ER+/ HER2+ matched breast cancer samples 
before and during therapy, the numbers are small and more are needed to consolidate the 
findings from this research.  
More recently in the Edinburgh breast research unit an immunohistochemistry based assay 
‘EA2Clin’, has been developed. It measures the level of pre-treatment IL6ST and on-
treatment MCM4 to assess proliferation.  This assay has been shown to identify responders 
and non responders to endocrine therapy, and to predict recurrence free survival and breast 
cancer specific overall survival. Preliminary data suggests that IL6ST can be used as a 
biomarker to identify ER+/ HER2+ breast cancers which will respond to endocrine therapy 
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Formalin fixed paraffin embedded (FFPE) biopsy tissue blocks were cut into 5-10 micrometre 
thick tissue sections and mounted to labelled microscope slides. Upon commencement of 
experiments, tissue was dewaxed in an autostainer.  
Antigen Retrieval for all markers was performed using sodium citrate solution within a 
pressure cooker, heated for 10 minutes in a microwave. Slides were subsequently washed in 
PBST solution on a laboratory shaker for 10 minutes. Tissue was then washed in hydrogen 
peroxide solution, again for 10 minutes on a laboratory shaker. Two additional 5 minute 
PBST washes were then performed.  
Each slide was assembled with a sequenza, followed by two further PBST washes at 5 minute 
intervals. DAKO total protein block was added to each slide and allowed to incubate for 30 
minutes to prevent non-specific antibody binding.  
Primary antibody calculations (in accordance with concentration provided in table) were 
determined and 150 micro-litres of antibody solution was added to sequenza. Following 
incubation two PBST washes were undertaken at 5 minute intervals.  
Secondary antibody was then added to each sequenza. This was permitted to incubate for 1 
hour and was followed with 2 more PBST washes.  
DAKO Dab chromogen and substrate buffer was used to localise the secondary antibody, 
thereby detecting the protein marker. A solution of 1:50 concentration (DAB: substrate 
buffer) was made and 150 microliters of this solution was added to each sequenza. The DAB 
was allowed to incubate for exactly 10 minutes.  
Following DAB incubation, slides were bathed in distilled water and then counterstained with 
Hematoxylin in an auto-stainer. Cover slips were added to each slide before they were 
















































































































































































































































































































































































































































































































































































































































































































Proliferation Gene List309 
























































MAPK Signalling Gene List289  
















































































PI3K Signalling Gene List 































































































































Questionnaire on HER2 Testing 
 
Please circle your answer for each question 
 
 
1. What is your grade?  
Consultant 
SpR 
Staff Grade/Ass Specialist  
 
2. How many breast cancers do you treat in one year? 
  <50 
  50-100  
  >100 
 
3. Which of the following best applies to the setting in which you work? 
  Specialist breast unit 
  Breast unit within a district general hospital 
  General surgical unit 
 






5. Do you have HER2 testing in your centre? 
  Yes 
  No 
 
6. Is HER2 testing done on the initial core biopsy in your centre? 
  Yes 
  No 
  Don’t know 
 
7. If HER 2 testing is done on the initial core biopsy in your centre, 
approximately what percentage of the cores you take from cancers is tested? 







8. If HER2 testing is done on the core biopsy, what percentage of HER2 results 
are available when you/or the multidisciplinary team make a decision as to 
whether the patient should have initial surgery or neoadjuvant therapy?  









9. Do you ONLY perform HER2 testing on the cancer after it has been removed 
by surgery?  
  Yes 
  No 
  Don’t know 
	
 
10. What percentage of ALL breast cancers in your centre are HER2 tested?  














12. Does your centre test with both the Hercept and SISH or FISH tests?  
Yes 
No 










13. In what percentage of patients do you have the full HER2 result (that 
includes immunohistochemistry and SISH or FISH testing) available when a 
patient is discussed at a multidisciplinary meeting when decisions are made 
on adjuvant therapy following a surgical procedure?  















15. What percentage of patients with large or locally advanced HER2 positive 
cancers in your centre who are given neoadjuvant chemotherapy also get 
neoadjuvant Herceptin?  







16. In a patient with a large HER2 positive invasive breast cancer what 
percentage of patients do you believe would get a complete pathological 
response if they were treated with neoadjuvant chemotherapy (6-8 cycles of 
chemotherapy and neoadjuvant Herceptin?  















17. What percentage of patients with an invasive cancer with involved axillary 
nodes who is given a 6-8 cycles of neoadjuvant chemotherapy and Herceptin 
do you believe will have complete response in previously involved lymph 
nodes?  







18. Do you think there is any advantage in adding neoadjuvant Herceptin to 





19. Would you like to make any specific comments about HER2 testing in your 
centre which you think might be valuable for us to know? 
 
If yes, please detail below: 
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